NISTIR 7880-1

NIST Micronutrients Measurement Quality Assurance Program Summer 2012 Comparability Studies

Results for Round Robin LXXII Fat-Soluble Vitamins and Carotenoids in Human Serum and Round Robin 37 Ascorbic Acid in Human Serum

David L. Duewer Jeanice B. Thomas

http://dx.doi.org/10.6028/NIST.IR.7880-1



NIST Micronutrients Measurement Quality Assurance Program Summer 2012 Comparability Studies

Results for Round Robin LXXII Fat-Soluble Vitamins and Carotenoids in Human Serum and Round Robin 37 Ascorbic Acid in Human Serum

David L. Duewer Jeanice B. Thomas Chemical Sciences Division Materials Measurement Laboratory

http://dx.doi.org/10.6028/NIST.IR.7880-1

March, 2013



U.S. Department of Commerce *Rebecca Blank, Acting Secretary*

(This page intentionally blank)

Abstract

The National Institute of Standards and Technology coordinates the Micronutrients Measurement Quality Assurance Program (MMQAP) for laboratories that measure fat- and water-soluble vitamins and carotenoids in human serum and plasma. This report describes the design of and results for the Summer 2012 MMQAP measurement comparability improvement studies: 1) Round Robin LXXII Fat-Soluble Vitamins and Carotenoids in Human Serum and 2) Round Robin 37 Total Ascorbic Acid in Human Serum. The materials for both studies were shipped to participants in June 2012; participants were requested to provide their measurement results by September 28, 2012.

Keywords

Human Serum Retinol, α -Tocopherol, γ -Tocopherol, Total and Trans - β -Carotene Total Ascorbic Acid

Table of Contents

| Abstract | ii |
|--|----|
| Keywords | ii |
| Table of Contents | |
| Introduction | 1 |
| Round Robin LXXII: Fat-Soluble Vitamins and Carotenoids in Human Serum | 1 |
| Round Robin 37: Vitamin C in Human Serum | 2 |
| References | 3 |
| | |
| Appendix A. Shipping Package Inserts for RR72 | A1 |
| Appendix B. Final Report for RR72 | B1 |
| Appendix C. All-Lab Report for RR72 | C1 |
| Appendix D. Representative Individualized Report for RR72 | |
| Appendix E. Shipping Package Inserts for RR37 | E1 |
| Appendix F. Final Report for RR37 | |
| Appendix G. "All-Lab Report" for RR37 | G1 |
| Appendix H. Representative "Individualized Report" for RR37 | |

Introduction

Beginning in 1988, the National Institute of Standards and Technology (NIST) has coordinated the Micronutrients Measurement Quality Assurance Program (MMQAP) for laboratories that measure fat- and water-soluble vitamins and carotenoids in human serum and plasma. The MMQAP provides participants with measurement comparability assessment through use of interlaboratory studies, Standard Reference Materials (SRMs) and control materials, and methods development and validation. Serum-based samples with assigned values for the target analytes (retinol, alphatocopherol, gamma/beta-tocopherol, *trans*- and total beta-carotene, and total ascorbic acid) and performance-evaluation standards are distributed by NIST to laboratories for analysis.

Participants use the methodology of their choice to determine analyte content in the control and study materials. Participants provide their data to NIST, where it is compiled and evaluated for trueness relative to the NIST value, within-laboratory precision, and concordance within the participant community. NIST provides the participants with a technical summary report concerning their performance for each exercise and suggestions for methods development and refinement. Participants who have concerns regarding their laboratory's performance are encouraged to consult with the MMQAP coordinators.

All MMQAP interlaboratory studies consist of individual units of batch-prepared samples that are distributed to each participant. For historical reasons these studies are referred to as "Round Robins". The MMQAP program and the nature of its studies are described elsewhere. [1,2]

Round Robin LXXII: Fat-Soluble Vitamins and Carotenoids in Human Serum

Participants in the MMQAP Fat-Soluble Vitamins and Carotenoids in Human Serum Round Robin LXXII comparability study (hereafter referred to as RR72) received one lyophilized and four liquid-frozen human serum test samples for analysis. Unless multiple vials were previously requested, participants received one vial of each serum. These sera were shipped on dry ice to participants in June 2012. The communication materials included in the sample shipment are provided in Appendix A.

Participants are requested to report values for all fat-soluble vitamin-related analytes that are of interest to their organizations. Not all participants report values for the target analytes, and many participants report values for non-target analytes.

The final report delivered to every participant in RR72 consists of three documents:

- A cover letter for the current study, a brief description of the other two documents, and a discussion of our analysis of the overall results that may be of broad interest. This cover letter is reproduced as Appendix B.
- The "All-Lab Report" that lists all of the reported measurement results, a number of consensus statistics for analytes reported by more than one participant, and the mean median and pooled SD from any prior distributions of the serum. This report also provides a numerical "score card" for each participant's measurement comparability for the more commonly reported analytes. This All-Lab Report is reproduced as Appendix C.

• An "Individualized Report" that graphically analyzes each participant's results for all analytes reported by at least five participants. This report also provides a graphical summary of their measurement comparability. The graphical tools used in the Individualized Report are described in detail elsewhere [3]. An example Individualized Report is reproduced as Appendix D.

Round Robin 37: Vitamin C in Human Serum

Participants in the MMQAP Vitamin C in Human Serum Round Robin 37 comparability study (hereafter referred to as RR37) received four frozen serum test samples, one frozen control serum, and a solid ascorbic acid control material for analysis. Unless multiple vials were previously requested, participants received one vial of each material. These sample materials were shipped on dry ice to participants in June 2012. The communication materials included in the sample shipment are provided in Appendix E.

The test and control serum materials were prepared by adding equal volumes of 10 % metaphosphoric acid (MPA) to human serum that had been spiked with ascorbic acid. While these samples contain some dehydroascorbic acid, its content is variable. Therefore, the participants report only total ascorbic acid (TAA, ascorbic acid plus dehydroascorbic acid). Participants are also encouraged to prepare calibration solutions from the supplied solid control to enable calibrating their serum measurements to the same reference standard.

The final report delivered to every participant in RR37 consists of three documents:

- A cover letter for the current study, a brief description of the other two documents, and a discussion of our analysis of overall results that may be of broad interest. This cover letter is reproduced as Appendix F.
- The "All-Lab Report" that summarizes all of the reported measurement results and provides several consensus statistics. This All-Lab Report is reproduced as Appendix G.
- An "Individualized Report" that graphically analyzes each participant's results for TAA, including a graphical summary of their measurement comparability. The graphical tools used in the Individualized Report are described in detail elsewhere [3]. An example Individualized Report is reproduced as Appendix H.

References

- 1 Duewer DL, Brown Thomas J, Kline MC, MacCrehan WA, Schaffer R, Sharpless KE, May WE, Crowell JA. NIST/NCI Micronutrients Measurement Quality Assurance Program: Measurement Repeatabilities and Reproducibilities for Fat-Soluble Vitamin-Related Compounds in Human Sera. Anal Chem 1997;69(7):1406-1413.
- 2 Margolis SA, Duewer DL. Measurement Of Ascorbic Acid in Human Plasma and Serum: Stability, Intralaboratory Repeatability, and Interlaboratory Reproducibility. Clin Chem 1996;42(8):1257-1262.
- 3 Duewer DL, Kline MC, Sharpless KE, Brown Thomas J, Gary KT, Sowell AL. Micronutrients Measurement Quality Assurance Program: Helping Participants Use Interlaboratory Comparison Exercise Results to Improve Their Long-Term Measurement Performance. Anal Chem 1999;71(9):1870-1878.

Appendix A. Shipping Package Inserts for RR72

The following three items were included in each package shipped to an RR72 participant:

- Cover letter
- Datasheet
- Packing List and Shipment Receipt Confirmation Form

The cover letter and datasheet were enclosed in a sealed waterproof bag along with the samples themselves. The packing list was placed at the top of the shipping box, between the cardboard covering and the foam insulation.



UNITED STATES DEPARTMENT OF COMMERCE National Institute of Standards and Technology Gaithersburg, Maryland 20899-

June 25, 2012

Dear Colleague:

Enclosed are samples for the second fat-soluble vitamins and carotenoids in serum study Round Robin LXXII (RR72) for the 2012 NIST Micronutrients Measurement Quality Assurance Program. The set of samples (Sera 387- 391) consists of one vial of lyophilized serum and one vial each of four liquid-frozen serum samples for analysis along with a form for reporting your results. These samples should be stored in the dark at or below –20 °C upon receipt.

When reporting your results, please submit one value for each analyte for a given serum sample. If a value obtained is below your limit of quantification, please indicate this result on the form by using NQ (Not Quantified). Results are due to NIST by **September 28, 2012**. Results received more than two weeks after the due date may not be included in the summary report for RR72. The feedback report concerning the study will be distributed in November 2012.

Samples should be allowed to stand at room temperature under subdued light until thawed. We recommend that sample mixing be facilitated with 3 to 5 min agitation in an ultrasonic bath or at least 15 min at room temperature with intermittent swirling. (CAUTION: Vigorous shaking will cause foaming and possibly interfere with accurate measurement. The rubber stopper contains phthalate esters that may leach into the sample upon intermittent contact of the liquid sample with the stopper. These esters absorb strongly in the UV region and elute near retinol in most LC systems creating analytical problems.) Water should not be added to the liquid-frozen samples.

For consistency, we request that laboratories use the following absorptivities (dL/g • cm): retinol, 1843 at 325 nm (ethanol); retinyl palmitate, 975 at 325 nm (ethanol); α -tocopherol, 75.8 at 292 nm (ethanol); γ -tocopherol, 91.4 at 298 nm (ethanol); α -carotene, 2800 at 444 nm (hexane); β -carotene, 2560 at 450 nm (ethanol), 2592 at 452 nm (hexane); and lycopene, 3450 at 472 nm (hexane).

Please report your results for RR72 by e-mail to david.duewer@nist.gov or fax to 301-977-0685. If you have questions or comments regarding this study, please call me at (301) 975-3120 or e-mail me at jbthomas@nist.gov.

Sincerely,

Jeanice Brown Thomas

Program Coordinator/Research Chemist

Analytical Chemistry Division

Material Measurement Laboratory



Round Robin LXXII: Human Sera NIST Micronutrients Measurement Quality Assurance Program

| Analyte | 387 | 388 | 389 | 390 | 391 | Units* |
|---------------------------------|-----|-----|-----|-----|-----|--------|
| total retinol | | | | | | |
| trans-retinol | | | | | | |
| retinyl palmitate | | | | | | |
| lpha-tocopherol | | | | | | |
| γ/β-tocopherol | | | | | | |
| δ-tocopherol | | | | | | |
| total β-carotene | | | | | | |
| trans-β-carotene | | | | | | |
| total cis-β-carotene | | | | | | |
| total α -carotene | | | | | | |
| total lycopene | | | | | | |
| trans-lycopene | | | | | | |
| total β-cryptoxanthin | | | | | | |
| total α-cryptoxanthin | | | | | | |
| total lutein | | | | | | |
| total zeaxanthin | | | | | | |
| total lutein&zeaxanthin | | | | | | |
| total coenzyme Q10 | | | | | | |
| ubiquinol (QH ₂) | | | | | | |
| ubiquinone (Qox) | | | | | | |
| phylloquinone (K ₁) | | | | | | |
| 25-hydroxyvitamin D | | | | | | |
| Phytoene | | | | | | |
| Phytofluene | | | | | | |
| | | | | | | |
| | | | | | | |

| • | 14/0 | profor | a/m | п |
|---|------|--------|-----|---|

Fax: 301-977-0685

Email: David.Duewer@NIST.gov

Were the samples frozen when received? Yes | No

Comments:

| Date: | | |
|-------|--|--|
| Date. | | |

Fat-Soluble Vitamins Round Robin LXXII NIST Micronutrients Measurement Quality Assurance Program

Packing List and Shipment Receipt Confirmation Form

This box contains: one vial each of the following five FSV M²QAP sera

| Serum | Form | Reconstitute? | Vial/Cap |
|-------|---------------|---------------|-----------------------|
| #387 | Lyophilized | Yes | 2 mL amber, red cap |
| #388 | Liquid frozen | No | 2 mL amber, green cap |
| #389 | Liquid frozen | No | 2 mL amber, red cap |
| #390 | Liquid frozen | No | 2 mL amber, gold cap |
| #391 | Liquid frozen | No | 2 mL amber, green cap |

- Please 1) Open the pack immediately
 - 2) Check that it contains all of the above samples
 - 3) Check if the vials are intact
 - 4) Store the sera at -20 °C or below until analysis
 - 5) Complete the following information
 - 6) Fax the completed form to us at 301-977-0685 (or email requested information to david.duewer@nist.gov)
- 1) Date this shipment arrived: _____
- 2) Are all five sera vials intact? Yes | No If "No", which one(s) were damaged?
- 3) Was there any dry-ice left in cooler? Yes | No
- 4) Did the samples arrive frozen? Yes | No
- 5) At what temperature are you storing the serum samples? ____ °C
- 6) When do you anticipate analyzing these samples? _____

Your prompt return of this information is appreciated.

The M²QAP Gang

Appendix B. Final Report for RR72

The following two pages are the final report as provided to all participants:

- Cover letter.
- An information sheet that:
 - o describes the contents of the "All-Lab" report,
 - o describes the content of the "Individualized" report,
 - o describes the nature of the test samples and details their previous distributions, if any, and
 - o summarizes aspects of the study that we believe may be of interest to the participants.

UNITED STATES DEPARTMENT OF COMMERCE National Institute of Standards and Technology Gaithersburg, Maryland 20899-

November 30, 2012

Dear Colleague:

Enclosed is the summary report of the results for round robin LXXII (RR72) of the 2012 NIST Micronutrients Measurement Quality Assurance Program (M²QAP) for the fat-soluble vitamins and carotenoids in human serum. Included in this report are: 1) a summary of data and measurement comparability scores for all laboratories, 2) a detailed graphical analysis of your results; and 3) a graphical summary of your measurement comparability. RR72 (Sera 387 - 391) consisted of one vial of lyophilized serum and one vial each of four liquid-frozen serum samples. Details regarding the samples can be found in the enclosed report.

Your overall measurement comparability is summarized in the "Score Card" summary, page 6 of the All Lab Report. Combined results rated 1 to 3 are within 1 to 3 standard deviations of the assigned value, respectively; those rated 4 are >3 standard deviations from the assigned value. Similar information is presented graphically in the "target plots" that are the last page of your Individualized Report. If you have concerns regarding your laboratory's performance, please contact us for consultation.

Samples for the first set of fat-soluble vitamins and carotenoids in serum interlaboratory exercise (RR73) of the 2013 M²QAP will be shipped **starting January 22, 2013**. Please contact us immediately if this schedule is problematic for your laboratory.

If you have questions or concerns regarding this report, please contact David Duewer at 301-975-3935; e-mail: david.duewer@nist.gov or me at 301-975-3120; e-mail: jbthomas@nist.gov; or fax: 301-977-0685.

Sincerely.

Jeanice Brown Thomas, M.B.A.

Research Chemist

Chemical Sciences Division

Material Measurement Laboratory

David L. Duewer, Ph.D.

Research Chemometrician

Chemical Sciences Division

Material Measurement Laboratory

Enclosures

Cc: L.C. Sander



The NIST MMQAP Round Robin LXXII (RR72) report consists of:

| Page | All-Lab Report |
|-------------|---|
| 1-4 | A listing of all results and statistics for analytes reported by more than one participant. |
| 5 | A listing of the analytes reported by only one participant and a legend for the list of results and statistics. |
| 6 | The text Comparability Summary ("Score Card") of measurement performance. |
| | |
| Page | Individualized Report |
| Page | Individualized Report |
| Page 1 | Your values, the number of labs reporting values, and our assigned values. |
| Page 1 2 to | ^ |
| 1 | Your values, the number of labs reporting values, and our assigned values. |

Samples. Five samples were distributed in RR72.

| Serum | Description | Prior Distributions |
|-------|---|---|
| 387 | Lyophilized, native serum prepared in 1999. Serum #380 is the liquid-frozen partner of this sample. | #270:RR49-3/01, #276:RR50-9/01, #367:RR68-9/10, #377:RR70-9/11 |
| 388 | Liquid-frozen, native serum prepared in 1999. Serum #377 is the lyophilized partner of this sample. | #267:RR49-9/00, #274:RR50-9/01, #368:RR68-9/10, #380:RR70-9/11 |
| 389 | Liquid-frozen, native, multi-donor, prepared in 2009. This is Level I of SRM 968e. | #357:RR66-9/09, #365:RR67-3/10, #375:RR69-3/11 |
| 390 | Liquid-frozen, native, single-donor serum prepared in 2011. This material was designed to have low contents of α - and β -carotene and lycopene but a high content of β -cryptoxanthin | #383:RR71 |
| 391 | Liquid-frozen, native, multi-donor, prepared in 2008 | #356:RR65-3/09, #360:RR66-9/09 |

Results

- 1) <u>SRM 968e Stability.</u> There was no significant change in the median level or measurement variability of any measurand in the SRM 968e Level I material.
- 2) <u>Lyophilized vs Liquid-frozen Stability</u>. After 13 years, there is no change in the median level or the measurement variability in any analyte in the lyophilized #387 material or the #388 liquid-frozen material prepared from the same serum pool. The analyte levels in the lyophilized material are slightly lower than in the liquid-frozen material due to reconstituting *with* 1.0 ml water rather than reconstituting *to* a total volume of 1.0 ml.

Appendix C. All-Lab Report for RR72

The following six pages are the "All-Lab Report" as provided to all participants, with two exceptions:

- the participant identifiers (Lab) have been altered.
- the order in which the participant results are listed has been altered.

The data summary in the "All-Lab Report" has been altered to ensure confidentiality of identification codes assigned to laboratories.

| y/β-Tocopherol, µg/mL | 387 388 389 390 391 | 2.44 1.90 1.83 | 2.21 2.30 1.79 1.72 2.40 | | | 2.10 2.20 1.70 1.60 2.30 | | 2.45 1.92 1.78 | 2.21 2.29 1.85 1.72 2.30 | | | | | 2.04 2.34 1.67 1.56 2.35 | | | | 2.23 2.27 1.77 1.85 2.44 | 2.30 2.19 1.66 1.75 2.14 | 2.08 1.69 1.55 | | | 2.78 2.16 1.96 | 1.69 1.67 | 2.05 2.17 1.90 1.78 2.18 | | | | 2 68 2 76 2 10 2 04 2 04 | 13 13 13 13 13 | 2.08 | 2.29 1.79 1.75 | 2.78 2.19 2.04 | 0.17 0.16 0.12 | 9 8 9 7 10 | 21 22 19 16 19 | 2.21 2.33 1.81 1.75 2.38 | 0.16 0.23 | 2.29 1.79 1.75 2. | 0.23 0.23 0.19 0.19 0.24 |
|--------------------------|---------------------|---------------------|-------------------------------|--------|-----------|--------------------------|----------------|-------------------------------|--------------------------|---------------------------|---------------------------|----------------|--------------------------|--------------------------|---------------------------|--------------------------|-------------------------------|---------------------------|--------------------------|-------------------------------|-------------------------------|----------------|------------------|-------------------------------|---------------------------|--------|--------------------------|--------|--------------------------|--|------------------------|-----------------------|---------------------|---------------------|------------|----------------|-------------------------------|-------------------------|------------------------|-------------------------------|
| a-Tocopherol, µg/mL | 387 388 389 390 391 | 5.89 6.19 6.66 6.72 | 6.20 6.58 6.92 7.34 10.50 | | 7.10 6.50 | 5.90 6.30 6.40 | 6.70 7.00 6.90 | 5.85 6.20 6.35 6.45 | 6.01 6.64 6.49 | 6.10 6.30 6.42 6.59 10.28 | 6.00 6.50 6.90 6.90 10.20 | 6.90 7.00 7.40 | 5.80 6.02 6.07 6.50 9.67 | 5.47 6.16 6.12 6.16 9.91 | 7.00 8.00 8.00 8.00 11.00 | 6.40 6.70 7.13 6.70 9.90 | | 6.93 7.29 7.71 8.49 12.59 | 6.67 6.00 6.16 6.96 9.11 | | 6.22 6.60 6.98 6.85 10.96 | 5.58 5.77 7.34 | 6.47 6.90 6.96 1 | 5.61 5.81 6.29 6.66 | 6.38 6.69 7.13 7.28 11.49 | | 5.10 6.30 5.50 7.20 8.60 | | 6 97 7 67 7 96 | 25 25 25 25 25 | 5.10 5.58 5.50 6.16 8 | 6.10 6.50 6.90 6.90 1 | 7.30 8.00 8.00 8.49 | 0.62 0.46 0.71 0.59 | 10 7 10 | 38 39 33 29 32 | 5.97 6.35 6.78 7.15 10.56 | 0.51 0.62 0.49 0.67 0. | 6.10 6.50 6.90 6.90 10 | 0.62 0.56 0.71 0.59 0.81 |
| Retinyl Palmitate, ug/mL | 387 388 389 390 391 | 0.020 0.016 0.016 | 0.024 0.020 0.009 0.008 0.035 | | | | | 0.017 0.022 0.014 0.015 0.044 | | | | | | | | | | | | 0.020 0.019 0.005 0.013 0.053 | | | | 0.020 0.022 0.012 0.013 0.048 | | | | | | л л | 0.019 0.005 0.008 0.03 | 0.020 0.012 0.013 | 0.022 0.016 0.016 | 0.002 0.005 0.003 | | 10 10 8 5 9 | 0.021 0.024 0.010 0.019 0.045 | 0.011 0.005 0.012 | 0.020 0.012 0.013 | 0.011 0.011 0.011 0.011 0.015 |
| trans-Retinol, ug/mL | 387 388 389 390 391 | | | | | | | | | | | | | | | | 0.534 0.542 0.281 0.374 0.629 | | | | 0.632 0.676 0.358 0.444 0.737 | | | | | | | | | | 0.542 0.281 0.374 0.62 | 0.319 0.409 | 0.676 0.358 0.444 | | | 12 7 0 | 7 0.657 0.347 | 0.040 0.048 0.035 0.097 | | |
| | 391 | 0.774 | 908.0 | 0.752 | 0.746 | 0.630 | 0.790 | 0.768 | 0.744 | 0.755 | 0.720 | 0.720 | 0.650 | 0.660 | 0.790 | na | ≥0.629 | 908.0 | 0.722 | 0.740 | 0.743 | 0.676 | 0.790 | 0.746 | 0.742 | 0.700 | 0.826 | 902 | 0.700 | | | | | | 2 | 30 | 0.740 | | 0.745 | 0.059 |
| ng/mL | 330 | 0.487 | | | | | | | | | | | | | | | ≥0.374 | | | 0.450 | | 0.464 | | | | | 0.542 | | 144.0 | | 0 | | | | 7 | 31 | 0.460 | | | 0.037 |
| Total Retinol, µg/mL | 389 | 0.374 | | | | | | | | | 0.340 | 0.360 | | | | | | | 0.406 | | 0.358 | 0.361 | 0.395 | | | | 0.392 | | 0.000 | | C | | | | . 2 | . 32 | 0.357 | | | 0.030 |
| Total | 388 | | | | | 0.580 | | | | | | 0.620 | | | | | 1 ≥0.542 | | | | | 0.670 | | | | | 0.783 | | 0.020 | | C | | | | 2 1 | 37 | 3 0.665 | | | 0.054 |
| | 387 | | | | | | | _ | _ | | | | | | | | \$ ≥0.534 | | | | | 0.531 | | | | | . 0.668 | 1 | | | 0 | | | | 4 | t 35 | t 0.636 | | | 0.052 |
| | Lab | FSV-BA | FSV-BB | FSV-BC | FSV-BD | FSV-BE | FSV-BF | FSV-BG | FSV-BJ | FSV-BK | FSV-BL | FSV-BM | FSV-BN | FSV-BO | FSV-BQ | FSV-BR | FSV-BS | FSV-BU | FSV-BV | FSV-BW | FSV-CC | FSV-CE | FSV-CG | FSV-CI | FSV-CZ | FSV-DD | FSV-DV | FSV-EE | 71-701 | - - - - - - - - - - | Z iğ | Median | Max | SD | S | Npast | Medianpast | SDpast | NAV | NAU |

| Total cis-β-Carotene, μg/mL Total α-Carotene, μg/mL | 387 388 389 390 391 387 | 0.019 0.022 0.007 0.001 0.016 0.016 0.020 0.006 0.010 0.046 | | | ; | 7 0.019 0.010 0 | bu bu bu bu | | | | 0.039 0.037 0.016 0.019 | 2000 | | 0.071 0.061 0.045 0.039 | 0.022 0.016 0.007 | 0.022 0.006 | 0.016 0.007 | | | 0.026 0.025 nq nq 0.017 0.025 0.023 0.009 | 0.027 0.026 0.013 0.020 | | | | | | 3 3 2 2 | 0.019 0.019 0.006 0.001 0.015 0.015 0.016 0.005 | 0.019 0.022 0.006 0.002 0.016 0.022 0.020 0.007 | 0.026 0.025 0.007 0.003 0.017 0.071 0.061 0.045 | 0.008 0.005 0.0 | 36 25 42 | 8 | 0.025 0.024 0.005 0.014 0.019 0.021 0.009 | 0.007 0.007 0.003 | 410 0 700 0 000 0 0018 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 |
|---|-------------------------|---|--------|-------------|--------|-----------------|-------------|--------|---------|----------|-------------------------|----------|--------|-------------------------------|-------------------|-------------|-------------|--------|--------|---|-------------------------|-------------|--------|--------|--------|--------|-----------|---|---|---|-----------------------|---|-------------|---|--|--|
| trans-β-Carotene, μg/mL | 387 388 389 390 391 | 0.440 0.475 0.083 0.042 0.262 | | | | | | | | | | | | 0.607 0.435 0.106 0.029 0.111 | | | | | | 0.416 0.444 0.082 0.040 0.252 | | | | | | | 4 4 4 4 4 | 0.435 0.080 0.029 | 0.450 0.083 0.041 | 0.475 0.106 0.042 | 0.015 0.003 0.001 0.0 | 4 3 3 4 10 | 10 11 8 5 8 | 0.471 0.083 0.044 | 0.037 0.038 0.006 0.004 0.012 | 0.432 0.450 0.083 0.041 0.241 |
| g/mL | 390 391 | 0.043 0.278 | | 0.050 0.340 | | | 0.054 0.254 | | | | 0.047 0.259 | | | ≥0.029 ≥0.111 | | | | | | | | 0.068 0.220 | | | | | 15 15 | | | | 0. | 21 11 | 18 21 | | 0.009 0.034 | 0.050 0.274 |
| Total β-Carotene, μg/mL | | 0.090.0 | | | | | 0.094 0 | | | | 0.086 0 | <u> </u> | | ≥0.106 ≥0 | 81 | | | | | | | 0.072 0 | | | | | 15 | | 88 | | | ======================================= | 22 | | 0.014 0 | 0.088.0 |
| Total β-C | | 0.496 | | 0.580 | | 0.541 | 0.495 | | | | 0.536 | | | ≥0.435 | 0.403 | | | | 0.465 | | | 0.407 | | | | | 15 | | | | 0.029 | 12 | 27 | | 0.067 | 0.496 |
| | 387 | 0.459 | | 0.620 | 0.534 | 0.514 | 0.457 | | | | 0.514 |) | | ≥0.607 | 0.406 | 0.482 | 0.505 | | 0.808 | 0.442 | 0.564 | 0.382 | | | | | 15 | 0.382 | 0.482 | 0.808 | 0.047 | 10 | 26 | 0.484 | 0.063 | 0.482 |
| 5-Tocopherol, µg/mL | 387 | 0.101 0.110 0.094 0.075 0.271 | | _ | _ | | | | | | | | | | | | | | | 0.188 0.189 0.164 0.255 0.179 | | | | | _ | | 3 3 3 | 0.110 0.094 0.059 | 0.117 0.100 0.075 | 0.188 0.189 0.164 0.255 0.271 | | | 9 | 0.109 0.110 0.063 | SD _{past} 0.040 0.101 0.025 0.043 0.026 | 0.109 0.117 0.100 0.075 0.265 |
| | Lab | FSV-BA FSV-BB | FSV-BC | FSV-BE | FSV-BF | FSV-BG | FSV-BJ | 70-70- | 12.V-BL | FOV-BIVI | FSV-BN | FSV-BO | FSV-BR | FSV-BS | FSV-BU | FSV-BV | FSV-BW | FSV-CC | FSV-CE | FSV-CG | FSV-CI | FSV-CZ | FSV-DD | FSV-DV | FSV-EE | FSV-FZ | z | Min | Median 0.109 | | SD | S | Npast | Medianpast 0.101 | SDpast | NAV |

| m 99, | 391 | 0.016 | | | | | | | | | | | | | | | | | | | | | | | | | 2 | 0.016 | 0.023 | 0.029 | | | ∞ | 0.020 | 0.009 | | |
|------------------------------|------------------------|-------------|------------------|--------|-------------------|--------|-------|--------|---|--------|---|--------|-------------------------------|-------|--------|-------|--------|--------|-------------------------------|--------|--------|--------|--------|--------|--------|--------|----|-----------|--------------|-----------|-------|----|-------|-------------------------|--------------------------|-------|-------|
| Total α-Cryptoxanthin, μg/mL | 390 | | | | | | | | | | | | | | | | | | | | | | | | | | 2 | 0.019 | 0.023 | 0.027 | | | 4 | 0.025 | 0.013 | | |
| toxant | 389 | | | | | | | | | | | | | | | | | | | | | | | | | | 2 | 0.016 | 0.019 | 0.022 | | | 4 | 0.018 | 0.003 | | |
| a-Cryp | 388 | | | | | | | | | | | | | | | | | | | | | | | | | | 2 | 0.023 | 0.028 | 0.033 | | | 2 | 0.027 | 0.005 0.003 | | |
| Total | 387 | 0.022 | | | | | | | | | | | | | | | | | | | | | | | | | 2 | 0.022 | 0.023 | 0.023 | | | 2 | 0.023 0.027 0.018 0.025 | 0.006 | | |
| /mL | 391 | 0.054 | | | 0.068 | 0.046 | | | 1 | 0.055 | | | 0.048 | 0.070 | 0.055 | | | | 0.085 | | | | | | | | 10 | 0.046 | 0.058 | 0.085 | 0.015 | 26 | 17 | 0.059 | 0.009 | 0.058 | 0.015 |
| hin, µg | 390 | 0.153 | | | 0.186 | 0.107 | | | | 0.164 | - | | 0.082 | 0.189 | 0.188 | | | | 0.201 | | | | | | | | 10 | 0.082 | 0.173 | 0.201 | 0.023 | 13 | 14 | 0.163 | 0.048 | 0.173 | 0.036 |
| otoxant | 389 | 0.046 | | | 0.056 | bu | | | 1 | 0.052 | 9 | | 0.073 | 0.071 | 0.044 | | | | 0.068 | | | | | | | | 6 | 0.044 | 0.056 | 0.073 | 0.015 | 26 | 17 | 0.050 | 0.011 | | 0.015 |
| Total β-Cryptoxanthin, μg/mL | 388 | 0.048 | | | 0.056 | bu | | | | 0.052 | | | 0.064 | 0.064 | 0.044 | | | | 0.067 | | | | | | | | 6 | 0.044 | 0.056 | 0.067 | 0.012 | 21 | 22 | | 0.010 | 0.056 | 0.013 |
| Total | 387 | 0.045 | | | 0.053 | bu | | | | 0.049 | 2 | | 0.080 | 090.0 | 0.044 | | | | 0.063 | | | | | | | | 6 | 0.044 | 0.050 | 0.080 | 900.0 | 12 | 21 | | 0.011 | | 0.012 |
| | 391 | 0.156 | | | 0.194 | | | | | | | | | | | | | | 0.205 | | | | | | | | 2 | 0.061 | 0.183 | 0.205 | 0.033 | 18 | œ | 0.180 | 0.021 | = | 0.033 |
| trans-Lycopene, µg/mL | 390 391 0.080 0.183 | 0.072 | | | 0.116 0.086 0.194 | | | | | | | | 0.082 0.065 0.088 0.043 0.061 | | | | | | 0.134 0.144 0.121 0.086 0.205 | | | | | | | | 2 | 0.043 | 0.080 | 0.086 | 0.009 | 7 | 9 | 0.138 0.116 0.083 0.180 | 0.019 | | 0.014 |
| copene | 389 | | | | 0.116 | | | | | | | | 0.088 | | | | | | 0.121 | | | | | | | | 2 | 0.088 | 0.113 | 0.121 | 0.011 | 10 | ∞ | 0.116 | 0.018 | | 0.020 |
| ans-Lyc | 388 | 0.125 | | | 0.152 | | | | | | | | 0.065 | | | | | | 0.144 | | | | | | | | 2 | 0.065 | 0.135 | 0.152 | 0.014 | 10 | 10 | 0.138 | 0.018 | | 0.024 |
| | 387 | 0.114 0.125 | | | 0.138 | | | | | | | | 0.082 | | | | | | 0.134 | | | | | | | | 2 | 0.082 | 0.123 | 0.138 | 0.016 | 13 | 1 | 0.124 | 0.023 | | 0.021 |
| | 391 | 0.303 | | | 0.190 0.367 | 0.415 | | | 1 | 0.385 | 2 | | 0.140 | 0.349 | 0.351 | 0.413 | | | 0.390 | | | | | | | | 11 | 0.140 | 0.351 | 0.415 | 0.058 | 16 | 16 | 0.376 | 0.046 | 0.351 | 0.078 |
| Total Lycopene, µg/mL | 390 | 0.164 | | | 0.190 | 0.200 | | | | 0.195 | - | | 0.077 | 0.177 | 0.192 | | | | 0.185 0.390 | | | | | | | | 11 | 0.077 | 0.177 | 0.200 | 0.022 | 12 | 13 | 226 0.171 | 0.036 | 0.177 | 0.045 |
| copene | 389 | 0.199 | | | 0.222 | 0.225 | | | | 0.230 | - | | 0.221 | | 0.216 | 0.216 | | | 0.236 | | | | | | | | 11 | 0.174 | 0.216 | 0.236 | 0.021 | 10 | 17 | 0.226 | 0.032 | 216 | 0.052 |
| otal Lyc | 388 | 0.218 | | | 0.245 | 0.270 | | | | 0.267 | - | | 0.186 | | 0.214 | | | | | | | | | | | | 11 | 0.175 | 0.218 | 0.270 | 0.040 | 18 | 22 | 0.233 | 0.037 | | 0.053 |
| | 387 | | | | | 0.238 | | | | 0.254 | | | 0.252 | | | 0.274 | | | 0.230 0.240 | | | | | | | | 11 | Min 0.171 | | Max 0.274 | | 15 | 2 | | | 0.230 | 0.055 |
| - | Lab FSV-BA | _ | FSV-BC FSV-BD | FSV-BE | _ | FSV-BJ | 70.00 | 13V-BL | _ | FSV-BN | | FSV-BR | | | FSV-BV | | FSV-CC | FSV-CE | FSV-CG | FSV-CI | FSV-CZ | FSV-DD | ESV-DV | FSV-FF | FSV-FK | FSV-FZ | z | Min | Median 0.230 | Max | SD | S | Npast | Medianpast 0.224 | SD _{past} 0.032 | | NAO |

| J 391 | | 021 | | | | | .776 | | 2 | 0.776 | 2.021 | | 0 | | |
|---|--------------------|-------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|------------------|--|--------------------------------------|--------|-------------|-------------|----------------------|-------------|---------|--------------------|
| Phylloquinone (K1), ng/mL 7 388 389 390 3 | | 2.986 3.365 0.631 0.262 2.021 | | | | | 1.433 1.429 0.263 0.091 0.776 | | 7 | 0.091 | | | 0 | | |
| ne (K1) 389 | | 631 0 | | | | | 263 0 | | 2 | 0.263 0 | | | 0 | | |
| loquinon 388 3 | | 365 0. | | | | | 129 0. | | 7 | | 3.365 0. | | 0 | | |
| Phyllo 7 38 | | 36 3.3 | | | | | 33 1.4 | | 2 | 33 1.4 | 3.3 3.3 | | 0 | | |
| 38 | | | 10 | | | | | | 8 | 3 1.433 | | + | 9 0 | 0 | + + |
| /mL 0 391 | | 0.900 1.16 0.86 | 4 0.95 | 4 0.58 | 2 0.91 | | 9 0.81 4 1.08 | 8 0.67 | 8 | 8 0.58 | 7 1.08 | .16 0.14 15 17 | 0 0 0 | 0.15 | 7 0.84 6 0.14 |
| 10, µg/r 390 | | 1.1 | 1.04 | 88 0.94 | 0 0.92 | | 1.19 | 86 0.88 | 8 | 38 0.88 | 36 1.37 | 0 | - | | 1 1.07 19 0.16 |
| Coenzyme Q10, µg/ml 37 388 389 390 | | 1 0.90 | 5 0.910 | 7 0.768 | 7 0.840 | | 3 0.840 8 0.881 | 8 1.436 | 8 | 7 0.768 | 3 1.436 | 2 0.052 5 6 | 0 857 | 6 0.073 | 5 0.891 |
| oenzyr 388 | | 0.930 0.91 | 0 0.86 | 3 0.47 | 0.720 0.67 | 0 0.97 | 0 0.83 7 1.28 | 3 0.68 | ω ω | 3 0.47 | 7 1.28 |)76 0.22 10 26 | 8 10 | 6 0.16 | 0 0.85 |
| C 387 | | 0.93 | 0.760 | 0.553 | | | 0.800 | 0.823 | | 0.553 | | 0.0 | 0 8 1 | | 0.790 |
| /mL 391 | 0.100 | | 0.100 | 0.091 | 0.104 | 0.076 | 0.136 | | 10 | 0.072 | 0.160 | 0.010 | 17 | 0.020 | 0.100 |
| hin, µg 390 | 0.113 | | 0.110 | 0.185 | 0.115 | 0.146 | 0.172 | | 10 | 0.104 | 0.185 | 0.016 | 14 0 131 | 0.041 | 0.118 |
| Total Lutein&Zeaxanthin, µg/mL 87 388 399 390 39 | 0.097 | | 0.104 | 0.159 | 0.206 | | 0.149 | | 10 | 0.092 | | 0.035 28 | 18 | | 0.125 |
| utein&Z | 0.121 (0.175 (| | 0.131 (| 0.128 (0.129 (| 0.170 (0.146 (| | 0.156 0.098 | | 10 | 0.098 | | 0.018 (| 21 | | 0.130 (0.027 (|
| Total Li | 0.121 0 0.170 0 | | 0.123 0 | 0.130 0 0.120 0. | 0.191 0 | | 0.146 0 0.095 0. | | 10 | 0.095 0 | | 0.010 0 8 | 20 0122 0 | | 0.127 0 0.026 0 |
| က | | | o . | | | o. | | | 4 | | | | | | |
| mL 391 | 0.053 | | | 0.019 | , 0.053 | | 0.026 0.031 0.018 | | | 5 0.018 | 0.053 | 0.025 | 0 | 0.015 | 0.036 |
| xanthin, µg/mL 389 390 | 0.050 0.066 | | | 0.015 | 0.053 0.057 | | 0.031 | | 4 | 0.015 | 0.066 | 0.026 59 | 0 | | 0.044 |
| xanthi 389 | 0.050 | | | 0.015 | 0.053 | | 0.026 | | 4 | 0.015 | 0.053 | 0.020 | 8 | 0.009 | 0.038 |
| Total Zea | 0.055 | | | 0.029 | 090.0 | | 0.032 | | 4 | 0.029 | 0.060 | 0.020 45 | 11 | 0.013 | 0.044 |
| Tot 387 | 0.054 (| | | 0.027 0.029 | 0.065 0.060 | | 0.026 0.032 | | 4 | 0.026 | 0.065 | 0.021 (51 | 10 | 0.012 | 0.041 (|
| 391 | 0.106 | | 081 | | | | | | 2 | 0.051 0 | | 0.038 0 46 | 6 090 0 | | 0.081 |
| | 07 0. | | 0.086 0.080 0.089 0.083 | 0.100 0.095 0.105 0.084 | 0.08 0. | | 073 0. | | 2 | 0.058 0. | 0.107 0. | 0.024 0. | 4 0 26 | | 0.089 0. |
| ž. | 0.120 0.098 0.107 | | 90 0.0 | 95 0.1 | 53 0.0 | | 99 0.0 | | 2 | | 53 0.1 | | 9 4 | 15 0.0 | 95 0.0 22 0.0 |
| Il Lutein | 0.0 | | 0.0 | 0.0 | 0 0.1 | | 0.0 | | 2 | 0.066 0.066 | 0.120 0.153 | 0.021 0.022 21 23 | 12 88 0.0 | 6 0.015 | 0 0.095 |
| | | | 3 0.08 | 3 0.10 | 0.126 0.110 0.153 0.058 0.051 | | 0.069 0.066 0.066 0.073 0.054 | | | 9 0.06 | 3 0.12 | 3 0.02 | 0 | 0.016 | 3 0.100 |
| 387 | 0.115 | | 0.078 | 0.093 | | | | | 2 | Min 0.069 | 0.126 | 0.033 | t 11 | t 0.020 | 0.093 |
| Lab | FSV-BA FSV-BB | FSV-BC FSV-BD FSV-BE | FSV-BG FSV-BG FSV-BJ FSV-BK | FSV-BL FSV-BM FSV-BN FSV-BO | FSV-BQ FSV-BR FSV-BS FSV-BU | FSV-BV FSV-BW | FSV-CC FSV-CE FSV-CG FSV-CI FSV-CZ FSV-DD | FSV-DV FSV-EE FSV-FK FSV-FZ | Z | Min 0.069 | Max | S S | Npast 0.086 | SDpast | NAV NAU |
| _ | ш ш | шшш | ᅩᇿ╙╙ | 正戊氏误 | пппп | 뜨 없 | пий - ий | . L L L L | | _ | _ | | Me | | |

Analytes Reported By One Laboratory

| Analyte | Lab | 387 | 388 | 389 | 390 | 391 |
|---------------------|--------|--------|--------|--------|--------|--------|
| 25-hydroxyvitamin D | FSV-BN | 0.0021 | 0.0040 | 0.0054 | 0.0063 | 0.0047 |
| Phytoene | FSV-BS | nd | nd | nd | 0.089 | 0.081 |
| Phytofluene | FSV-BS | 0.123 | 0.119 | 0.132 | 0.110 | 0.116 |

| Term | Legend |
|--------------------|---|
| N | Number of (non-NIST) quantitative values reported for this analyte |
| Min | Minimum (non-NIST) quantitative value reported |
| Median | Median (non-NIST) quantitative value reported |
| Max | Maximum (non-NIST) quantitative value reported |
| SD | Adjusted median absolute deviation from the median of the non-NIST results |
| CV | Coefficient of Variation for (non-NIST) results: 100*SD/Median |
| | |
| N_{past} | Mean of N(s) from past RR(s) |
| Medianpast | Mean of Median(s) from past RR(s) |
| SD _{past} | Pooled SD from past RR(s) |
| | |
| NAV | NIST Assigned Value |
| | = (Median + NIST)/2 for analytes reported by NIST |
| | = Median for analytes reported by ≥ 5 labs but not NIST |
| NAU | NIST Assigned Uncertainty: $\sqrt{(S^2 + S_{btw}^2)}$ |
| | S is the maximum of (0.05*NAV, SD, SD _{past} , eSD) and S _{btw} is the standard |
| | deviation between Median and NIST. The expected long-term SD, eSD, |
| | is defined in: Duewer et al., Anal Chem 1997;69(7):1406-1413. |
| | |
| nd | Not detected (i.e., no detectable peak for analyte) |
| nq | Detected but not quantitatively determined |
| ≥x | Concentration greater than or equal to x |
| | |
| italics | Not explicitly reported but calculated by NIST from reported values |

Comparability Summary

| Lab | TR | аТ | g/bT | bC | аС | TLy | TbX | TLu | L&Z |
|--------|----|----|------|----|----|-----|-----|-----|-----|
| FSV-BA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 1 |
| FSV-BB | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| FSV-BC | 1 | | | | | | | | |
| FSV-BD | 1 | 1 | | | | | | | |
| FSV-BE | 2 | 1 | 1 | 2 | | | | | |
| FSV-BF | 2 | 1 | | 2 | | | | | |
| FSV-BG | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | 1 |
| FSV-BJ | 1 | 1 | 1 | 1 | | 1 | 2 | 1 | |
| FSV-BK | 1 | 1 | | | | | | | |
| FSV-BL | 2 | 1 | | | | | | | |
| FSV-BM | 1 | 1 | | | | | | | |
| FSV-BN | 1 | 1 | | 1 | 2 | 1 | 1 | | 2 |
| FSV-BO | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| FSV-BQ | 1 | 2 | | | | | | | |
| FSV-BR | 1 | 1 | | | | | | | |
| FSV-BS | 3 | | | 3 | 4 | 2 | 2 | 2 | 2 |
| FSV-BU | 2 | 3 | 1 | 2 | 1 | 1 | 1 | | 1 |
| FSV-BV | 2 | 2 | 1 | 1 | 1 | 1 | 1 | | 1 |
| FSV-BW | 1 | 1 | 4 | 1 | 1 | 1 | | | |
| FSV-CC | 1 | 1 | | | | | | | |
| FSV-CE | 2 | 2 | | 3 | | | | | |
| FSV-CG | 1 | 1 | 2 | 1 | 1 | 1 | 2 | | 2 |
| FSV-CI | 1 | 1 | 1 | 1 | 2 | | | 2 | 2 |
| FSV-CZ | 1 | 1 | 1 | 2 | | | | | |
| FSV-DD | 1 | | | | | | | | |
| FSV-DV | 2 | 2 | | | | | | | |
| FSV-FK | 1 | 2 | | | | | | | |
| FSV-FZ | 1 | 2 | 3 | | | | | | |
| n | 28 | 25 | 13 | 16 | 11 | 11 | 10 | 5 | 10 |

| | TR | аΤ | g/bT | bC | аC | TLy | TbX | TLu | L&Z |
|-----|----|----|---------|----|----|-----|-----|-----|-----|
| % 1 | 68 | 72 | 77 8 | 56 | 73 | 91 | 70 | 60 | 50 |
| % 2 | 25 | 24 | 8 | 31 | 18 | 9 | 30 | 40 | 50 |
| % 3 | 7 | 4 | 8 | 13 | 0 | 0 | 0 | 0 | 0 |
| % 4 | 0 | 0 | 8 | 0 | 9 | 0 | 0 | 0 | 0 |

| Label | Definition |
|-------|--|
| Lab | Participant code |
| TR | Total Retinol |
| аТ | α -Tocopherol |
| g/bT | γ/β-Tocopherol |
| bC | Total β-Carotene |
| tbC | trans-β-Carotene |
| аC | Total α-Carotene |
| TLy | Total Lycopene |
| TbX | Total β-Cryptoxanthin |
| TLu | Total Lutein |
| TZ | Total Zeaxanthin |
| L&Z | Total Lutein & Zeaxanthin |
| | |
| n | number of participants providing quantitative data |
| % 1 | Percent of CS = 1 (within 1 SD of medians) |
| % 2 | Percent of CS = 2 (within 2 SD of medians) |
| % 3 | Percent of CS = 3 (within 3 SD of medians) |
| % 4 | Percent of CS = 4 (3 or more SD from medians) |
| | |

"Comparability Score"

The Comparability Score (CS) summarizes your measurement performance for a given analyte relative to the consensus medians in this study. CS is the average distance (in units of standard deviation) of your measurement performance characteristics from the consensus performance. CS is calculated when the number of quantitative values you reported, N_{you}, is at least two and at least six participants reported quantitative values for the analyte.

We define CS as follows:

$$\begin{split} &CS = MINIMUM\!\!\left(4,\!INTEGER\!\!\left(1\!+\!\sqrt{C^2\!+\!AP^2}\right)\right) \\ &C = Concordance = \frac{\displaystyle\sum_{i=1}^{N_{you}}\!\frac{You_i\!-\!Median_i}{NAU_i}}{N_{you}} \\ &AP = Apparent\ Precision = \sqrt{\frac{\displaystyle\sum_{i=1}^{N_{you}}\!\left(\frac{You_i\!-\!Median_i}{NAU_i}\right)^2}{N_{you}-1}} \end{split}$$

For further details, please see

NAU = NIST Assigned Uncertainty

Duewer DL, Kline MC, Sharpless KE, Brown Thomas J, Gary KT. Micronutrients Measurement Quality Assurance Program: Helping participants use interlaboratory comparison exercise results to improve their long-term measurement performance. Anal Chem 1999;71(9):1870-8.

Appendix D. Representative Individualized Report for RR72

Each participant in RR72 received an "Individualized Report" reflecting their reported results. Each report included a detailed analysis for analytes that were assayed by at least five participants. The following analytes met this criterion in RR72:

- Total Retinol
- Retinyl Palmitate
- α-Tocopherol
- γ/β -Tocopherol
- Total β-Carotene
- Total α-Carotene
- Total Lycopene
- trans-Lycopene
- Total β-Cryptoxanthin
- Total Lutein
- Total Lutein & Zeaxanthin
- Coenzyme Q10

The following twelve pages are the "Individualized Report" for the analytes evaluated by participant FSV-BA.

Individualized Round Robin LXXII Report: FSV-BA

Summary

| | Ser | Serum 387 | | Ser | um 388 | | Ser | Serum 389 | | Ser | Serum 390 | _ | Ser | Serum 391 | |
|-------------------------|-------|-----------|---------|-------|----------------|----|-------|-----------|----|-------|-----------|----|-------|-----------|----|
| Analyte | ≻ | NAV n | _ | You | You NAV n | _ | You | NAV n | _ | You | NAV | ⊆ | You | NAV | ⊆ |
| Total Retinol | 0.664 | 0.654 | 27 | 0.711 | 0.678 | 27 | 0.374 | 0.361 | 27 | 0.487 | 0.464 | 27 | 0.774 | 0.745 | 26 |
| Retinyl Palmitate | 0.02 | | 2 | 0.0 | 0.0 | 2 | 0.0 | 0.0 | 2 | 0.02 | 0.01 | | | 0.04 | 2 |
| α-Tocopherol | | | 25 | 6.19 | 6.50 | 25 | 99.9 | 06.9 | 25 | 6.72 | 6.90 | 25 | | 10.42 | 25 |
| γ/β-Tocopherol | | 2.235 | 13 | 2.438 | 2.290 | 13 | 1.901 | 1.794 | 13 | 1.831 | 1.750 | | | 2.350 | 13 |
| ō-Tocopherol | 0.101 | 0.109 | က | 0.110 | 0.117 | က | 0.094 | 0.100 | က | 0.075 | 0.075 | က | 0.271 | 0.265 | က |
| Total β-Carotene | 0.459 | 0.482 15 | 15 | 0.496 | 0.496 | 15 | 0.000 | 0.088 | 15 | 0.043 | 0.050 | 15 | 0.278 | 0.274 | 15 |
| trans-β-Carotene | 0.440 | 0.432 | 4 | 0.475 | 0.450 | 4 | 0.083 | 0.083 | 4 | 0.042 | 0.041 | 4 | 0.262 | 0.241 | 4 |
| Total cis-β-Carotene | 0.019 | 0.019 | က | 0.022 | 0.022 | က | 0.007 | | 7 | 0.001 | | 7 | 0.016 | 0.016 | က |
| Total α-Carotene | 0.016 | 0.022 | 7 | | 0.020 | 7 | | 0.007 | 7 | 0.010 | 0.014 | 7 | 0.046 | 0.049 | 12 |
| Total Lycopene | | 0.230 | 7 | 0.205 | 0.218 | 7 | 0.202 | 0.216 | 7 | | 0.177 | 7 | 0.318 | 0.351 | 7 |
| trans-Lycopene | | 0.123 | 2 | 0.135 | | 2 | 0.113 | 0.113 | 2 | 0.080 | 0.080 | 2 | 0.183 | 0.183 | 2 |
| Total β-Cryptoxanthin | 0.050 | 0.050 | <u></u> | 090.0 | 0.056 | 6 | 0.057 | 0.056 | 6 | 0.182 | 0.173 | 10 | 0.076 | 0.058 | 10 |
| Total α-Cryptoxanthin | 0.023 | | 7 | 0.033 | | 7 | 0.02 | | 7 | 0.027 | | 7 | 0.029 | | |
| Total Lutein&Zeaxanthin | 0.121 | 0.127 | 10 | _ | 0.121 0.130 10 | 10 | 0.097 | 7 0.125 | 10 | 0.113 | 0.118 | 10 | 0.100 | 0.100 | 10 |

You: Your reported values for the listed analytes (micrograms/milliliter)

NAV: NIST Assigned Values, here equal to this RR's median

n: Number of non-NIST laboratories reporting quantitative values for this analyte in this serum

Please check our records against your records. Send corrections and/or updates to...


Micronutrients Measurement Quality Assurance Program National Institute of Standards and Technology

100 Bureau Drive Stop 8392 Gaithersburg, MD 20899-8392 USA


Tel: (301) 975-3935 Fax: (301) 977-0685

Email: david.duewer@nist.gov


ILR_RR72_FSV-BA.xlsx, Page 1 / 12




| rum | <u>Comments</u> | <u>History</u> |
|-----|---|--------------------------------|
| 387 | Lyophilized, same native pool as #388 | 49#270, 50#276, 68#367, 70#377 |
| 388 | Fresh-frozen, same native pool as #387 | 49#267, 50#274, 68#368, 70#380 |
| 389 | Fresh-frozen, native, multi-donor: SRM 968e I | 66#357, 67#365,69#375 |
| 390 | Fresh-frozen, native, single-donor | 71#383 |
| 391 | Fresh-frozen, native, multi-donor | 65#356, 66#360 |




| rum | <u>Comments</u> | <u>History</u> |
|-----|---|--------------------------------|
| 387 | Lyophilized, same native pool as #388 | 49#270, 50#276, 68#367, 70#377 |
| 388 | Fresh-frozen, same native pool as #387 | 49#267, 50#274, 68#368, 70#380 |
| 389 | Fresh-frozen, native, multi-donor: SRM 968e I | 66#357, 67#365,69#375 |
| 390 | Fresh-frozen, native, single-donor | 71#383 |
| 391 | Fresh-frozen, native, multi-donor | 65#356, 66#360 |




| rum | <u>Comments</u> | <u>History</u> |
|-----|---|--------------------------------|
| 387 | Lyophilized, same native pool as #388 | 49#270, 50#276, 68#367, 70#377 |
| 388 | Fresh-frozen, same native pool as #387 | 49#267, 50#274, 68#368, 70#380 |
| 389 | Fresh-frozen, native, multi-donor: SRM 968e I | 66#357, 67#365,69#375 |
| 390 | Fresh-frozen, native, single-donor | 71#383 |
| 391 | Fresh-frozen, native, multi-donor | 65#356, 66#360 |




| <u>:rum</u> | <u>Comments</u> | <u>History</u> |
|-------------|---|--------------------------------|
| 387 | Lyophilized, same native pool as #388 | 49#270, 50#276, 68#367, 70#377 |
| 388 | Fresh-frozen, same native pool as #387 | 49#267, 50#274, 68#368, 70#380 |
| 389 | Fresh-frozen, native, multi-donor: SRM 968e I | 66#357, 67#365,69#375 |
| 390 | Fresh-frozen, native, single-donor | 71#383 |
| 391 | Fresh-frozen, native, multi-donor | 65#356, 66#360 |




| rum | <u>Comments</u> | <u>History</u> |
|-----|---|--------------------------------|
| 387 | Lyophilized, same native pool as #388 | 49#270, 50#276, 68#367, 70#377 |
| 388 | Fresh-frozen, same native pool as #387 | 49#267, 50#274, 68#368, 70#380 |
| 389 | Fresh-frozen, native, multi-donor: SRM 968e I | 66#357, 67#365,69#375 |
| 390 | Fresh-frozen, native, single-donor | 71#383 |
| 391 | Fresh-frozen, native, multi-donor | 65#356, 66#360 |




| <u>:rum</u> | <u>Comments</u> | <u>History</u> |
|-------------|---|--------------------------------|
| 387 | Lyophilized, same native pool as #388 | 49#270, 50#276, 68#367, 70#377 |
| 388 | Fresh-frozen, same native pool as #387 | 49#267, 50#274, 68#368, 70#380 |
| 389 | Fresh-frozen, native, multi-donor: SRM 968e I | 66#357, 67#365,69#375 |
| 390 | Fresh-frozen, native, single-donor | 71#383 |
| 391 | Fresh-frozen, native, multi-donor | 65#356, 66#360 |




| rum | <u>Comments</u> | <u>History</u> |
|-----|---|--------------------------------|
| 387 | Lyophilized, same native pool as #388 | 49#270, 50#276, 68#367, 70#377 |
| 388 | Fresh-frozen, same native pool as #387 | 49#267, 50#274, 68#368, 70#380 |
| 389 | Fresh-frozen, native, multi-donor: SRM 968e I | 66#357, 67#365,69#375 |
| 390 | Fresh-frozen, native, single-donor | 71#383 |
| 391 | Fresh-frozen, native, multi-donor | 65#356, 66#360 |



| <u>:rum</u> | <u>Comments</u> | <u>History</u> |
|-------------|---|--------------------------------|
| 387 | Lyophilized, same native pool as #388 | 49#270, 50#276, 68#367, 70#377 |
| 388 | Fresh-frozen, same native pool as #387 | 49#267, 50#274, 68#368, 70#380 |
| 389 | Fresh-frozen, native, multi-donor: SRM 968e I | 66#357, 67#365,69#375 |
| 390 | Fresh-frozen, native, single-donor | 71#383 |
| 391 | Fresh-frozen, native, multi-donor | 65#356, 66#360 |




| rum | <u>Comments</u> | <u>History</u> |
|-----|---|--------------------------------|
| 387 | Lyophilized, same native pool as #388 | 49#270, 50#276, 68#367, 70#377 |
| 388 | Fresh-frozen, same native pool as #387 | 49#267, 50#274, 68#368, 70#380 |
| 389 | Fresh-frozen, native, multi-donor: SRM 968e I | 66#357, 67#365,69#375 |
| 390 | Fresh-frozen, native, single-donor | 71#383 |
| 391 | Fresh-frozen, native, multi-donor | 65#356, 66#360 |



| rum | <u>Comments</u> | <u>History</u> |
|-----|---|--------------------------------|
| 387 | Lyophilized, same native pool as #388 | 49#270, 50#276, 68#367, 70#377 |
| 388 | Fresh-frozen, same native pool as #387 | 49#267, 50#274, 68#368, 70#380 |
| 389 | Fresh-frozen, native, multi-donor: SRM 968e I | 66#357, 67#365,69#375 |
| 390 | Fresh-frozen, native, single-donor | 71#383 |
| 391 | Fresh-frozen, native, multi-donor | 65#356, 66#360 |

Individualized Round Robin LXXII Report: FSV-BA Graphical Comparability Summary

Set 1 of 33



Appendix E. Shipping Package Inserts for RR37

The following five items were included in each package shipped to an RR37 participant:

- Cover letter
- Protocol for Preparation and Analysis of the Ascorbic Acid Solid Control Material
- Preparation and Validation of Ascorbic Acid Solid Control Material Datasheet
- Analysis of Control Materials and Test Samples Datasheet
- Packing List and Shipment Receipt Confirmation Form

The cover letter, preparation protocol, and the two datasheets were enclosed in a sealed waterproof bag along with the samples themselves. The packing list was placed at the top of the shipping box, between the cardboard covering and the foam insulation.



UNITED STATES DEPARTMENT OF COMMERCE National Institute of Standards and Technology Gaithersburg, Maryland 20899-

June 25, 2012

Dear Colleague:

The samples within this package constitute Vitamin C Round Robin 37 (RR37) of the 2012 Micronutrients Measurement Quality Assurance Program. RR37 consists of four vials of frozen serum test samples (#371, #372 #373, and #374), one vial each of two frozen control serum samples (CS #3 and CS #4), and one vial of ascorbic acid solid control material (Control). Please follow the attached protocols when you prepare and analyze these samples. If you cannot prepare the solid control solutions gravimetrically, please prepare equivalent solutions volumetrically and report the exact volumes used. (Routine 0.5 g gravimetric measurements are generally 10-fold more accurate than routine 0.5 mL volumetric measurements.)

Please use the *control sera* to validate the performance of your measurement system <u>before</u> you analyze the *test samples*. The target value for CS #3 is $(15.5 \pm 1.6; 13.9 \text{ to } 17.1) \, \mu\text{mol/L}$ and the target for CS #4 is $(46.1 \pm 4.6; 41.5 \text{ to } 50.7) \, \mu\text{mol/L}$. We expect your results for both of these controls to be within this \pm 10% target range. If either of your result is significantly outside this range, your analysis system may not be suited to the analysis of MPA-preserved samples. In this case, please do **not** proceed to the analysis of the *test samples* but contact us at 301-975-3120 or <u>jbthomas@nist.gov</u>.

Please be aware that sample contact with any oxidant-contaminated surface (vials, glassware, etc.) may degrade your measurement system's performance (SA Margolis and E Park, "Stability of Ascorbic Acid in Solutions in Autosampler Vials", *Clinical Chemistry* 2001, 47(8), 1463-1464). You should suspect such degradation if you observe unusually large variation in replicate analyses.

Please report your results (using the attached form) for RR37 by e-mail to <u>david.duewer@nist.gov</u> or fax to 301-977-0685 by **September 28, 2012**. If you have questions or comments regarding this study, please call me at (301) 975-3120 or e-mail me at <u>jbthomas@nist.gov</u>.

Sincerely,

Jeanice Brown Thomas

Program Coordinator/Research Chemist

Analytical Chemistry Division

Chemical Science and Technology Laboratory

Enclosures: Protocols, Preparation and Analysis of Control Materials and Analysis of Test Samples

RR37 Report Form for Ascorbic Acid Solid Control Material Preparation

RR37 Report Form for Control Material and Test Sample Analyses



Micronutrient Measurement Quality Assurance Program for Vitamin C

Please Read Through Completely BEFORE Analyzing Samples

Protocol for Preparation and Analysis of the Ascorbic Acid Solid Control Material

The ascorbic acid solid control material (in the amber vial) should be prepared and used in the following manner:

- 1) Prepare at least 500 mL of 5% mass fraction metaphosphoric acid (MPA) in distilled water. This solution will be referred to as the "Diluent" below.
- 2) Weigh 0.20 to 0.22 g of the ascorbic acid solid control material to 0.0001 g (if possible), dissolve it in the Diluent in a 100 mL volumetric flask, and dilute with the Diluent to the 100 mL mark. Weigh the amount of Diluent added to 0.1 g. Record the weights. The resulting material will be referred to as the "Stock Solution" below.
- 3) Prepare three dilute solutions of the Stock Solution as follows:
 - <u>Dilute Solution 1:</u> Weigh 0.500 mL of the Stock Solution to 0.0001 g into a 100 mL volumetric flask; dilute with Diluent to the 100 mL mark. Record the weight.
 - <u>Dilute Solution 2:</u> Weigh 0.250 mL of the Stock Solution to 0.0001 g into a 100 mL volumetric flask; dilute with Diluent to the 100 mL mark. Record the weight.
 - <u>Dilute Solution 3:</u> Weigh 0.125 mL of the Stock Solution to 0.0001 g into a 100 mL volumetric flask; dilute with Diluent to the 100 mL mark. Record the weight.
- 4) Calculate and record the total ascorbic acid concentrations, [TAA], in these Dilute Solutions. If you follow the above gravimetric preparation directions, the [TAA] in μmol/L is calculated:

$$[\mathsf{TAA}]_{\mathsf{DS}} = \frac{ \big(\mathsf{g} \, \mathsf{Stock} \, \, \mathsf{Solution} \, \mathsf{in} \, \mathsf{Dilute} \, \mathsf{Solution} \big) \cdot \big(\mathsf{g} \, \mathsf{AA} \, \mathsf{in} \, \mathsf{Stock} \, \mathsf{Solution} \big) \cdot \big(\mathsf{56785} \, \, \mu \mathsf{mol/g} \cdot \mathsf{L} \big) }{ \big(\mathsf{g} \, \mathsf{AA} \, \mathsf{in} \, \mathsf{Stock} \, \mathsf{Solution} \big) + \big(\mathsf{g} \, \mathsf{Diluent} \, \mathsf{in} \, \mathsf{Stock} \, \mathsf{Solution} \big) }$$

For example, if you prepared the Stock Solution with 0.2000 g of solid ascorbic acid and 103.0 g of Diluent, then 0.5 mL of the Stock Solution should weigh (0.2+103)/200 = 0.52 g and $[TAA]_{DS1} = (0.52 \text{ g})(0.2 \text{ g}) \cdot (56785 \text{ } \mu\text{mol/g} \cdot \text{L})/(0.2 + 103 \text{ g}) = 57.2 \text{ } \mu\text{mol/L}$. Likewise, 0.25 mL of the Stock Solution should weigh 0.26 g and $[TAA]_{DS2} = 29.4 \text{ } \mu\text{mol/L}$ and 0.125 mL should weigh 0.13 g and $[TAA]_{DS3} = 14.2 \text{ } \mu\text{mol/L}$.

5) Measure the ultraviolet absorbance spectrum of Dilute Solution 1 against the Diluent as the blank using paired 1 cm path length cuvettes. Record the absorbance at 242, 243, 244, and 245 nm. Record the maximum absorbance (A_{max}) within this region. Record the wavelength (λ_{max}) at which this maximum occurs.

The extinction coefficient ($E^{1\%}$) of ascorbic acid at λ_{max} (using a cell with a 1 cm path length) of Dilute Solution #1 can be calculated:

$$E^{1\%}(\frac{dL}{g \cdot cm}) = \frac{\left(A_{max}\right) \cdot \left(\left(g \text{ AA in Stock Solution}\right) + \left(g \text{ Diluent in Stock Solution}\right)\right)}{\left(g \text{ Stock Solution in Dilute Solution 1}\right) \cdot \left(g \text{ AA in Stock Solution}\right)}$$

If your spectrophotometer is properly calibrated, λ_{max} should be between 243 and 244 nm and $E^{1\%}$ should be 550 ± 30 dL/g·cm. If they are not, you should recalibrate the wavelength and/or absorbance axes of your spectrophotometer and repeat the measurements.

- 6) Measure and record the concentration of total ascorbic acid in all three dilute solutions and in the 5% MPA Diluent in duplicate using *exactly* the same method that you will use for the serum control materials and test samples, including any enzymatic treatment. We recommend that you analyze these solutions in the following order: Diluent, Dilute Solution 1, Dilute Solution 2, Dilute Solution 3, Dilute Solution 3, Dilute Solution 2, Dilute Solution 1, Diluent.
 - a) Compare the values of the duplicate measurements. *Are you satisfied that your measurement precision is adequate?*
 - b) Compare the measured with the calculated [TAA] values. This is most conveniently done by plotting the measured values on the y-axis of a scatterplot against the calculated values on the x-axis. The line through the four {calculated, measured} data pairs should go through the origin with a slope of 1.0. Are you satisfied with the agreement between the measured and calculated values?

Do <u>not</u> analyze the serum control materials or test samples until you are satisfied that your system is performing properly!

Once you have confirmed that your system is properly calibrated, analyze the serum controls CS #3 and CS #4 (see protocol below). The target range for CS #3 is (15.5 \pm 1.6; 13.9 to 17.1) μ mol/L and the target range for CS #4 is (46.1 \pm 4.6; 41.5 to 50.7) μ mol/L.

If either of your measured values is not within its target range, please review your sample preparation procedure and whether you followed *exactly* the same measurement protocol the solutions prepared from the solid control material as you used for these serum controls. If the protocols differ, please repeat from Step 6 using the proper protocol. If the proper protocol was used, your measurement system may not be suitable for MPA-preserved samples; please contact us at 301-975-3120 or jbthomas@nist.gov.

Do <u>not</u> analyze the test samples until you are satisfied that your system is performing properly and is suitable for the analysis of MPA-preserved serum!

Protocol for Analysis of the Serum Control Materials and Test Samples

The *serum control material* and *test samples* are in sealed ampoules. They were prepared by adding equal volumes of 10% MPA to spiked human serum. We have checked the samples for stability and homogeneity. Only the total ascorbic acid is stable. While these samples contain some dehydroascorbic acid, its content is variable. Therefore, only <u>total ascorbic acid</u> should be reported. The *serum control material* and *test samples* should be defrosted by warming at 20 °C for not more than 10 min otherwise some irreversible degradation may occur.

Each *serum test sample* contains between 0.0 and 80.0 μ mol of total ascorbic acid/L of solution. The total ascorbic acid in each ampoule should be measured in duplicate. Please report your results in μ mol/(L of the sample solution) rather than μ mol/(L of serum NIST used to prepare the sample).

| Participant #: | Date: |
|----------------|-------|
|----------------|-------|

Vitamin C Round Robin 37 NIST Micronutrient Measurement Quality Assurance Program

Preparation and Validation of Ascorbic Acid Solid Control Material

STOCK SOLUTION

| Mass of ascorbic acid in the Stock Solution | g |
|---|---------|
| Mass of 5% MPA Diluent added to the 100 mL volumetric flask | g |
| DILUTE SOLUTION 1 | |
| Mass of added stock solution (0.5 mL) | g |
| Mass of 5% MPA Diluent added to the 100 mL volumetric flask | g |
| Absorbance of Dilute Solution 1 at 242 nm | AU |
| Absorbance of Dilute Solution 1 at 243 nm | AU |
| Absorbance of Dilute Solution 1 at 244 nm | AU |
| Absorbance of Dilute Solution 1 at 245 nm | AU |
| Absorbance of Dilute Solution absorbance maximum | AU |
| Wavelength of maximum absorbance | nm |
| Calculated E ^{1%} | dL/g·cm |
| Calculated [TAA] _{DS1} | μmol/L |
| DILUTE SOLUTION 2 | |
| Mass of added stock solution (0.25 mL) | g |
| Mass of 5% MPA Diluent added to the 100 mL volumetric flask | g |
| Calculated [TAA] _{DS2} | μmol/L |
| DILUTE SOLUTION 3 | |
| Mass of added stock solution (0.125 mL) | g |
| Mass of 5% MPA Diluent added to the 100 mL volumetric flask | g |
| Calculated [TAA] _{DS3} | umol/L |

Please return by September 28, 2012

Fax: 301-977-0685

| Participant #: | Date: |
|----------------|-------|
|----------------|-------|

Vitamin C Round Robin 37 NIST Micronutrient Measurement Quality Assurance Program

Analysis of Control Materials and Test Samples

| Sample | Replicate 1 | Replicate 2 | Units |
|------------------------|-------------|-------------|--|
| Dilute Solution 1 | | | μmol/L of Dilute Solution |
| Dilute Solution 2 | | | μmol/L of Dilute Solution |
| Dilute Solution 3 | | | μmol/L of Dilute Solution |
| 5% MPA Diluent | | | μmol/L of Diluent |
| CS # 3 | | | μ mol/L of Sample Target: (15.5 ±1.6) μ mol/L |
| CS # 4 | | | μmol/L of Sample Target: (46.1 ±4.6) μmol/L |
| Serum Test Sample #371 | | | μmol/L of Sample |
| Serum Test Sample #372 | | | μmol/L of Sample |
| Serum Test Sample #373 | | | μmol/L of Sample |
| Serum Test Sample #374 | | | μmol/L of Sample |

Were samples frozen upon receipt? Yes | No

Analysis method: HPLC-EC | HPLC-Fluor DAB | HPLC-OPD | HPLC-UV | AO-OPD | Other If "Other", please describe:

Nature of samples you typically analyze: native | MPA-preserved | DTT-preserved | Other If "Other", please describe:

COMMENTS:

Please return by September 28, 2012

Fax: 301-977-0685

Email: david.duewer@nist.gov

Vitamin C Round Robin 37 NIST Micronutrients Measurement Quality Assurance Program Packing List and Shipment Receipt Confirmation Form

This box contains one vial each of the following **seven** VitC M²QAP samples:

| Label | Form |
|-----------|-----------------------------------|
| VitC #371 | Liquid frozen (1:1 serum:10% MPA) |
| VitC #372 | Liquid frozen (1:1 serum:10% MPA) |
| VitC #373 | Liquid frozen (1:1 serum:10% MPA) |
| VitC #374 | Liquid frozen (1:1 serum:10% MPA) |
| CS #3 | Liquid frozen (1:1 serum:10% MPA) |
| CS #4 | Liquid frozen (1:1 serum:10% MPA) |
| Control | Solid AA |

- Please 1) Open the pack immediately
 - 2) Check that it contains one vial each of the above samples
 - 3) Check if the samples arrived frozen
 - 4) Store the samples at -20 °C or below until analysis
 - 5) Complete the following information
 - 6) Fax the completed form to us at 301-977-0685 (or email requested information to david.duewer@nist.gov)

| 1) Date this shipment arrived: | - |
|--------------------------------|---|
|--------------------------------|---|

- 2) Are all of the vials intact? Yes | No If "No", which one(s) were damaged?
- 3) Was there any dry-ice left in cooler? Yes | No
- 4) Did the samples arrive frozen? Yes | No
- 5) At what temperature are you storing the samples? C
- 6) When do you anticipate analyzing these samples? _____

Your prompt return of this information is appreciated.

The M²QAP Gang

Mail: M²QAP

NIST, Stop 6392 Gaithersburg, MD 20899-6392

Appendix F. Final Report for RR37

The following five pages are the final report as provided to all participants:

- Cover letter.
- An information sheet that:
 - o describes the contents of the "All-Lab" report,
 - o describes the content of the "Individualized" report,
 - o describes the nature of the test samples and details their previous distributions, if any, and
 - o summarizes aspects of the study that we believe may be of interest to the participants.



UNITED STATES DEPARTMENT OF COMMERCE National Institute of Standards and Technology Gaithersburg, Maryland 20899-

December 7, 2012

Dear Colleague:

Enclosed is the summary report of the results for Round Robin 37 (RR37) for the measurement of total ascorbic acid (TAA, ascorbic acid plus dehydroascorbic acid) in human serum. Included in this report are a summary of data for all laboratories and an individualized summary of your laboratory's measurement performance. The robust median is used to estimate the consensus value for all samples, the "adjusted median absolute deviation from the median" (MADe) is used to estimate the expected standard deviation, and we estimate the coefficient of variation (CV) as $100 \times MADe/median$.

RR37 consisted of four test samples (#371, #372,, #373, and #374), one vial each of two frozen control serum control samples (CS #3 and CS #4), and one vial of solid control material (Control) for preparation of TAA control solutions. Details regarding the samples can be found in the enclosed report.

If you have concerns regarding your laboratory's performance, we suggest that you obtain and analyze a unit of Standard Reference Material (SRM) 970 Vitamin C in Frozen Human Serum. SRM 970 can be purchased from the NIST SRM Program at www.nist.gov/srm; phone: 301-975-6776; fax: 301-948-3730. If your measured values do not agree with the certified values, we suggest that you contact us for consultation.

Samples for the first vitamin C round robin (RR38) of the 2013 MMQAP will be shipped starting January 22, 2013. Please contact us immediately if this schedule is problematic for your laboratory.

If you have questions or concerns regarding this report, please contact David Duewer at david.duewer@nist.gov or me at jbthomas@nist.gov, 301-975-3120, or fax: 301-977-0685.

Sincerely,

Jeanice Brown Thomas, M.B.A.

Research Chemist

Analytical Chemistry Division

Material Measurement Laboratory

David L. Duewer, Ph.D.

Research Chemometrician Analytical Chemistry Division

Material Measurement Laboratory

Enclosures

cc: L. C. Sander



The NIST MMQAP Vitamin C Round Robin 37 (RR37) report consists of:

| Page | "Individualized" Report |
|------|---|
| 1 | Summary of your reported values for the nominal 55 mmol/L solution you prepared from the ascorbic acid solid control sample, the serum control sample, and the four serum test samples. |
| 2 | Graphical summary of your RR37 sample measurements. |
| Page | "All-Lab" Report |
| 1 | A tabulation of results and summary statistics for total ascorbic acid [TAA] in the RR37 samples and control/calibration solutions. |

Serum-Based Samples. Two serum controls and four test samples were distributed in RR37.

| | 1 |
|-------|--|
| CS#3 | a (13.9 to 17.1) µmol/L material ampouled in late 2009 |
| CS#4 | a (41.5 to 50.7) µmol/L material ampouled in late 2009 |
| S37:1 | SRM 970 level 1, ampouled in mid-1998, previously distributed as an "Unknown" in RRs 11 to 16, 19, 20 23, 25, 29, 31, and 34 |
| S37:2 | Ampouled in late 2001, previously distributed in RRs 17, 18, 20, 22, 23, 27, and 31 |
| S37:3 | SRM 970 level 2, ampouled in mid-1998, previously distributed as an "Unknown" in RRs 11 to 15, 18, 20 22, 25, 29, and 36 $$ |
| S37:4 | Ampouled in late 2001, previously distributed in RRs 16, 17, 20, 21, 23, 27, and 30 |

Results.

- 1) All participants who prepared the four 5% metaphosphoric acid (MPA) control/calibration solutions (the three "Dilute Solutions" and the "Diluent") did so correctly. The criteria used to evaluate this success are: the density of the 5% MPA solution (\approx 1.03 gm/mL), the observed wavelength maximum of "Dilute Solution #1" (\approx 244 nm), the observed absorbance at that maximum (\approx 0.58), and the calculated $E^{1\%}$ #1" (\approx 560 dL/g·cm).
- 2) The Measured = a+b*Gravimetric calibration parameters for the control/calibration solutions (columns 10 to 13 of the All-Lab Report) indicate that the measurement systems for all participants are linear (R^2 close to 1 and the root-mean-square (RMS) residual close to 0.0) and well calibrated (intercepts close to 0 and slopes close to 1).
- 3) The Measured = p+q*Median regression parameters for samples S37:1 to S37:4 (columns 23 to 26 of the All-Lab Report) confirm the linearity of all measurement systems (R² close to 1 and RMS close to 0.0). However, the intercepts and slopes continue to indicate that there are systematic differences in the response of the various measurement procedures to the TAA in the 5% aqueous metaphosphoric acid (MPA) of the test samples.
- 4) The variability of the measured values after calibration to the control solutions (the final 6 columns of the All-Lab Report) continues to be as great or greater than that of the measured values themselves. The primary source of the systematic differences in response of the measurement procedures appears to be the presence of serum components in the sample matrix, not the MPA preservative. On this basis, we intend to drop the standard solution arm of the MMQAP Vitamin C Round Robin studies beginning with RR38.

Appendix G. "All-Lab Report" for RR37

The following single page is the "All-Lab Report" as provided to all participants, with two exceptions:

- the participant identifiers (Lab) have been altered.
- the order in which the participant results are listed has been altered.

The data summary in the "All-Lab Report" has been altered to ensure confidentiality of identification codes assigned to laboratories.

Micronutrients Measurement Quality Assurance Program for Total Ascorbic Acid "Round Robin" 37 - Fall 2012

| | | S37:4 | 42.2 | 44.8 | 47.9 | 46.7 | 45.2 | 47.2 | 50.5 | 42.1 | 40.4 | 6 | 45.2 | 3.2 | 40.4 | 42.2 | 45.2 | 47.2 | 50.5 | 4.0 | 6 |
|-------------------------------|--------------------------|--------------------|----------|----------|----------|----------|----------|----------|----------------------|----------|----------|---|-----------|---------|----------|----------|----------|----------|----------|----------|------|
| | | S37:3 S | 26.7 | 26.9 | 27.6 | 27.4 | 25.8 | 29.5 | 32.2 | 25.9 | 23.9 | 6 | 27.3 | 2.4 | 23.9 | 25.9 | 26.9 | 27.6 | 32.2 | 1.4 | 2 |
| | µmol/L | S37:2 S | 19.7 | 21.7 | 22.1 | 21.8 | 20.0 | 21.6 | 26.4 | 21.0 | 17.1 | 6 | 21.3 | 2.5 | 17.1 | 20.0 | 21.6 | 21.8 | 26.4 | 8.0 | 4 |
| | Calibrated, µmol/l | S37:1 S | 7.7 | 8.7 | 8.3 | 8.3 | 9.7 | 10.1 | 11.5 | 8.5 | 7.1 | 6 | 8.7 | 1.4 | 7.1 | 7.7 | 8.3 | 8.7 | 11.5 | 6.0 | 11 |
| | Cali | CS#4 S | 47.2 | 46.6 | 47.5 | 46.0 | 46.2 | 45.8 | 53.3 | 41.9 | 40.4 | 6 | 46.1 | 3.6 | 40.4 | 45.8 | 46.2 | 47.2 | 53.3 | 9.1 | 3 |
| | | CS#3 C | 15.9 | 12.6 | 15.6 | 14.9 | 14.8 | 16.5 | 22.7 | 14.9 | 13.1 | 6 | 15.7 | 2.9 | 12.6 | 14.8 | 14.9 | 15.9 | 22.7 | 4. | 10 |
| | an an | RMS | 0.5 | 0.7 | 1.1 | 8.0 | 1.1 | 1.0 | 9.0 | 0.5 | 1.1 | | | | | | | | | | |
| | q*Medi≀ | \mathbb{R}^2 RI | 0.999 | 0.999 | 0.997 | 0.998 | 966.0 | 0.997 | 0.999 | 666 | 0.996 | | | | | | | | | | |
| | Measured = p+q*Median | Slope | .00 0.1 | 0.99 0. | .11 | 1.10 0. | .03 0. | .00 | .08 | 0.96 0. | 0.96 0. | | | | | | | | | | |
| | Measur | Inter SI | -0.48 1 | 0.20 | -1.36 | -1.50 | -2.13 1 | -0.07 | 2.09 1 | 0.44 0 | -1.75 0 | | | | | | | | | | |
| Samples | | S37:4 Ir | 44.0 -(| 44.7 | 48.9 | 48.2 | 44.7 | 44.9 | 50.1 | 43.3 | 41.8 -1 | 6 | 45.6 | 2.8 | 41.8 | 44.0 | 44.7 | 48.2 | 50.1 | 2.0 | 2 |
| Sarr | | S37:3 S | 27.8 | 26.8 | 28.2 | 28.1 | 25.4 | 27.8 | 31.7 | 26.6 | 24.8 | 6 | 27.5 | 2.0 | 24.8 | 26.6 | 27.8 | 28.1 | 31.7 | 1.5 | 2 |
| | J/Jowr | S37:2 S | 20.5 | 21.7 | 22.6 | 22.2 | 19.7 | 20.2 | 25.9 | 21.5 | 17.7 | 6 | 21.3 | 2.3 | 17.7 | 20.2 | 21.5 | 22.2 | 25.9 | 1.7 | 8 |
| | Measured, µmol/ | S37:1 S | 8.0 | 8.8 | | | 7.4 | 9.1 | 10.9 | 8.5 | 7.3 | 6 | 8.5 | 1.1 | 7.3 | 8.0 | 8.5 | 8.8 | | 0.7 | 8 |
| | Mea | CS#4 | 49.2 | 46.5 | 48.4 | 47.5 | 45.7 | 43.6 | 53.0 | 43.2 | 41.8 | 6 | 46.5 | 3.5 | 41.8 | 43.6 | 46.5 | 48.4 | 53.0 | 4.1 | 6 |
| | | CS#3 C | 16.5 | 12.6 | 16.0 | 15.1 | 14.6 | 15.2 | 22.2 | 15.1 | 13.5 | 6 | 15.7 | 2.7 | 12.6 | 14.6 | 15.1 | 16.0 | 22.2 | 1.3 | 6 |
| | | | 541.6 | . 260.3 | . 228.0 | 569.4 | 260.8 | | | 2.653 | 551.4 | 7 | . 222.3 | 8.7 | 541.6 | 554.7 | _ | 2.095 | 569.4 | 5.6 | 0.5 |
| ution 1 | otometry | E ^{1%} | _ | | | _ | | |)a 349.9a | | | 7 | | _ | | | 33 559. | _ | _ | | 5.2 |
| Dilute Solution 1 | Spectrophotometry | . A _{max} | 0.5510 | 5 0.5990 | 0.5952 | 6 0.6140 | 3 0.5933 | | a 0.340 ^a | 9 0.5694 | 0.5450 | 7 | 3 0.5810 | 7 0.026 | 0 0.5450 | 2 0.5602 | 5 0.5933 | 8 0.5971 | 0 0.6140 | 6 0.0307 | |
| | | λтах | 243. | 243.5 | 244. | 243.6 | 243.3 | | 255ª | 243.9 | 242. | | 243.3 | 0.7 | 242.0 | 243.2 | 243.5 | 243.8 | 244.0 | 9.0 | 0.26 |
| MPA | Density | g/mL | 1.036 | 1.030 | 1.024 | 1.026 | 1.031 | 1.031 | 1.015 | 1.032 | 1.028 | 6 | 1.028 | 0.006 | 1.015 | 1.026 | 1.030 | 1.031 | 1.036 | 0.0 | 0.33 |
| | irav | RMS | 0.4 | 0.8 | 0.2 | 9.0 | 0.4 | 2.2 | 1.5 | 0.5 | 0.2 | z | Average | SD | Min | %25 | Median | %75 | Max | eSD | ટ |
| | Measured = $a + b$ *Grav | \mathbb{R}^2 | 1.000 | 0.999 | 1.000 | 1.000 | 1.000 | 0.994 | 0.997 | 1.000 | 1.000 | | ¥ | | | | _ | | | | |
| | sured = | Slope | 1.04 | 0.99 | 1.02 | 1.04 | 0.99 | 0.97 | 1.00 | 1.04 | 1.04 | | | | | | | | | | |
| Control / Calibration Samples | Mea | Inter | -0.03 | 0.11 | 0.15 | -0.43 | -0.19 | -0.69 | -0.61 | -0.35 | -0.07 | | | | | | | | | | |
| ion Sa | 1/1 | MPA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 | 6 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | |
| alibrat | d, μmo | Dil:3 | 15.0 | 14.5 | 15.8 | 16.8 | 14.7 | 13.5 | 13.4 | 13.5 | 14.3 | 6 | 14.6 | 1.2 | 13.4 | 13.5 | 14.5 | 15.0 | 16.8 | 4. | 10 |
| trol / C | Measured, µmol/L | Dil:2 | 29.9 | 31.2 | 31.3 | 32.1 | 29.4 | 23.4 | 26.8 | 30.2 | 30.2 | 6 | 29.4 | 2.7 | 23.40 | 29.35 | 30.18 | 31.23 | 32.15 | 1.6 | 2 |
| Con | Me | Dil:1 | 0.09 | 60.1 | 61.7 | 63.7 | 59.7 | 53.9 | 55.5 | 59.7 | 58.2 | 6 | 59.2 | 3.0 | 53.9 | 58.2 | 59.7 | 60.1 | 63.7 | 2.2 | 4 |
| | 1/1 | Dil:3 | 14.8 | 14.9 | 15.2 | 16.8 | 14.9 | 13.8 | 15.1 | 13.9 | 13.8 | 6 | | 0.9 | 13.8 | 13.9 | 14.9 | 15.1 | 16.8 | 0.4 | က |
| | Grav, µmol/L | Dil:2 | 28.3 | 30.3 | 30.6 | 31.8 | 30.2 | 27.7 | 28.1 | 29.2 | 29.4 | 6 | 29.5 14.8 | 1.3 | 27.67 | 28.33 | 29.39 | 30.31 | 31.83 | 1.6 | 2 |
| | Gra√ | Dil:1 | 8.73 | 60.7 | 9.09 | 61.2 | 60.1 | 55.3 | 55.1 | 57.8 | 56.1 | 6 | 58.3 | 2.4 | 55.1 | 56.1 | 57.8 | 9.09 | 61.2 | 3.7 | 9 |
| ļ | | Date | 25/09/12 | 06/08/12 | 20/08/12 | 15/08/12 | 12/09/12 | 27/09/12 | 29/08/12 | 12/09/12 | 10/08/12 | Z | Average (| SD | Min | %25 | Median (| %75 (| Max | MADe | ટ |
| | | ă | | _ | | ` | • | | _ | | | | Ave | | | | Μ̈́ | | | 2 | |
| | | Lab | VC-MA | VC-MB | VC-MC | VC-MG | VC-MH | NC-M | VC-MJ | VC-MN | VC-NM | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | |

a) 5% Trichloroacetic acid solution

Appendix H. Representative "Individualized Report" for RR37

Each participant in RR37 received an "Individualized Report" reflecting their reported results. The following two pages are the "Individualized Report" for participant "VC-MA".

Vitamin C "Round Robin" 37 Report: Participant VC-MA

Dilute Solution 1

Control/Calibration Solutions

MPA


Set 1 of 9

| Date RR | | | | | | Density | | Spec | trophoto | metry | Ym | ' X _{grav} | | |
|---|----------|----|---------|--------|------|---------|---------|-----------------|-----------|-----------------|-------|---------------------|----------------------|---------------|
| 10324/10 32 HPIC-EC 1.035 242.0 0.566 545.1 0.3 1.03 1.000 0.48 | Date | RR | | Method | | g/mL | ĺ | λ_{max} | A_{max} | E ^{1%} | Inter | Slope | R^2 | SEE |
| Date RR Sample Rep. Feel Mean Department | | | HPLC-EC | | | 1.035 | | 242.0 | | 545.1 | 0.3 | | 1.000 | 0.46 |
| 09/25/12 37 HPLC-EC 1.039 24/20 0.568 547.7 0.0 1.03 1.000 0.24 0.000 | 09/27/10 | 33 | HPLC-EC | | | 1.037 | | 244.0 | 0.560 | 540.5 | 0.4 | 1.08 | 1.000 | 0.43 |
| 1.035 | 02/28/11 | 34 | HPLC-EC | | | 1.039 | | 244.0 | 0.575 | 555.2 | 0.6 | 1.14 | 1.000 | 0.78 |
| Date RR Sample Rep. | 08/24/11 | 35 | HPLC-EC | | | 1.039 | | 242.0 | 0.568 | 547.7 | 0.0 | 1.03 | 1.000 | 0.24 |
| Date RR Sample Rep. Rep. Fed Mean SDage SDag | 02/02/12 | 36 | HPLC-EC | | | 1.035 | | 244.0 | 0.561 | 550.5 | -0.4 | 1.05 | 1.000 | 0.55 |
| Date RR Sample Rep. | 09/25/12 | 37 | HPLC-EC | | | 1.035 | | 243.0 | 0.551 | 541.6 | 0.0 | 1.04 | 1.000 | 0.41 |
| Date Date OBC Sample Rep. Rep. Feat Mean SD Sample Sa | | | | | Mean | 1.037 | • | 243.2 | 0.56 | 546.8 | | Po | oled SEE | 0.50 |
| Dele RR | | | | | SD | 0.002 | | 1.0 | 0.01 | 5.6 | | | | |
| 09/23/98 11 | | | | | | | [TAA] m | nmol/Lsa | ample | | | | | |
| 09/23/98 11 | Date | RR | | Sample | | r | | | _ | SD_{dup} | N | Mean | SD _{repeat} | SD_{reprod} |
| 09/77/01 13 S13:1 8.4 8.5 1.0 8.5 0.1 09/27/01 14 S14:3 8.0 7.7 1.0 7.8 0.2 09/18/01 15 S15:1 8.9 8.7 1.0 8.8 0.1 11/18/02 16 S16:1 8.8 8.8 1.0 8.8 0.1 11/18/02 20 S20:3 8.3 8.1 1.0 8.2 0.5 02/23/04 20 S20:3 8.3 8.1 1.0 8.2 0.1 08/28/06 25 S25:1 8.7 8.5 1.0 8.6 0.2 08/11/08 29 S29:2 8.3 8.4 1.0 8.3 0.1 09/26/12 37 S37:1 8.0 8.1 1.0 8.0 0.0 09/23/98 11 S11:2 50.7 4.77 0.5 24.6 1.1 04/02/99 12 S12:2 49.5 45.9 0.5 22.9 1.3 09/27/01 14 S14:4 25.7 26.4 1.0 26.0 0.5 09/27/01 15 S15:2 25.4 25.6 1.0 25.5 0.2 09/20/20 20 S20:4 25.9 25.2 1.0 25.6 0.1 09/23/04 20 S20:4 29.4 1.0 25.6 0.1 09/27/01 27 S17:2 23.7 1.0 22.4 0.1 09/27/01 28 S12:2 29.4 1.0 25.6 0.1 09/20/01 28 S29:3 22.4 2.9 4.0 25.4 0.1 09/20/01 28 S29:3 22.5 2.4 2.6 1.1 09/27/01 38 S16:1 2.7 2.7 2.7 1.0 2.8 4.0 1.0 09/27/01 38 S16:3 28.8 29.2 1.0 25.6 0.1 09/23/04 20 S20:4 25.9 25.2 1.0 25.5 0.5 03/08/05 22 S22:4 29.4 1.0 25.6 0.1 09/27/01 38 S16:1 2.7 2.7 2.7 1.0 2.2 4.0 0.1 09/27/01 39 S29:3 25.5 0.2 2.9 0.3 02/23/04 20 S20:4 29.4 29.4 1.0 25.6 0.1 09/25/12 37 S37:3 27.9 27.8 1.0 25.6 0.1 09/25/12 37 S37:3 27.9 27.8 1.0 25.6 0.1 09/25/12 37 S37:3 27.9 27.8 1.0 25.6 0.1 09/25/12 37 S37:3 22.2 2.2 2.7 0.2 2.7 0.0 10/17/05 23 S23:3 49.8 48.8 1.0 49.3 0.7 09/25/12 37 S37:2 2.1 0.4 0.4 0.4 0.4 09/18/02 16 S16:3 49.9 44.9 1.0 44.4 0.4 09/30/04 20 S20:1 25.1 24.1 1.0 24.6 0.7 09/25/12 37 S37:2 2.2 2.7 1.0 25.6 0.4 09/25/12 37 S37:2 2.2 2.7 1.0 25.6 0.4 09/26/12 37 S37:3 2.2 2.4 1.0 2.9 0.8 10/05/07 27 S27:1 2.2 2.3 7.0 2.2 0.7 09/25/12 37 S37:2 2.2 2.4 0.0 2.2 0.7 09/25/12 37 S37:2 2.2 2.4 0.0 2.2 0.7 09/25/12 37 S37:2 2.2 2.4 0.0 49.4 0.4 09/30/04 20 S20:1 25:1 24.1 1.0 49.4 0.4 09/30/04 20 S20:2 52:2 52:2 4.0 0.4 0.4 0.4 09/30/04 20 S20:2 52:2 52:2 5.0 0.4 0.4 0.4 0.4 09/30/04 20 S20:2 52:2 52:2 52:4 0.0 49.4 0.0 0.0 08/30/04 20 S20:1 52:4 4.1 0.0 49.4 0.4 09/30/04 20 S20:2 50:5 50:6 50.0 1.0 49.3 0.7 09/25/12 37 S37:2 50:0 50:0 50:0 50:0 50:0 50:0 50:0 50 | 09/23/98 | 11 | | S11:1 | | | | | | | 14 | 8.2 | 0.3 | |
| 09/77/01 13 S13:1 8.4 8.5 1.0 8.5 0.1 09/27/01 14 S14:3 8.0 7.7 1.0 7.8 0.2 09/18/01 15 S15:1 8.9 8.7 1.0 8.8 0.1 11/18/02 16 S16:1 8.8 8.8 1.0 8.8 0.1 11/18/02 20 S20:3 8.3 8.1 1.0 8.2 0.5 02/23/04 20 S20:3 8.3 8.1 1.0 8.2 0.1 08/28/06 25 S25:1 8.7 8.5 1.0 8.6 0.2 08/11/08 29 S29:2 8.3 8.4 1.0 8.3 0.1 09/26/12 37 S37:1 8.0 8.1 1.0 8.0 0.0 09/23/98 11 S11:2 50.7 4.77 0.5 24.6 1.1 04/02/99 12 S12:2 49.5 45.9 0.5 22.9 1.3 09/27/01 14 S14:4 25.7 26.4 1.0 26.0 0.5 09/27/01 15 S15:2 25.4 25.6 1.0 25.5 0.2 09/20/20 20 S20:4 25.9 25.2 1.0 25.6 0.1 09/23/04 20 S20:4 29.4 1.0 25.6 0.1 09/27/01 27 S17:2 23.7 1.0 22.4 0.1 09/27/01 28 S12:2 29.4 1.0 25.6 0.1 09/20/01 28 S29:3 22.4 2.9 4.0 25.4 0.1 09/20/01 28 S29:3 22.5 2.4 2.6 1.1 09/27/01 38 S16:1 2.7 2.7 2.7 1.0 2.8 4.0 1.0 09/27/01 38 S16:3 28.8 29.2 1.0 25.6 0.1 09/23/04 20 S20:4 25.9 25.2 1.0 25.5 0.5 03/08/05 22 S22:4 29.4 1.0 25.6 0.1 09/27/01 38 S16:1 2.7 2.7 2.7 1.0 2.2 4.0 0.1 09/27/01 39 S29:3 25.5 0.2 2.9 0.3 02/23/04 20 S20:4 29.4 29.4 1.0 25.6 0.1 09/25/12 37 S37:3 27.9 27.8 1.0 25.6 0.1 09/25/12 37 S37:3 27.9 27.8 1.0 25.6 0.1 09/25/12 37 S37:3 27.9 27.8 1.0 25.6 0.1 09/25/12 37 S37:3 22.2 2.2 2.7 0.2 2.7 0.0 10/17/05 23 S23:3 49.8 48.8 1.0 49.3 0.7 09/25/12 37 S37:2 2.1 0.4 0.4 0.4 0.4 09/18/02 16 S16:3 49.9 44.9 1.0 44.4 0.4 09/30/04 20 S20:1 25.1 24.1 1.0 24.6 0.7 09/25/12 37 S37:2 2.2 2.7 1.0 25.6 0.4 09/25/12 37 S37:2 2.2 2.7 1.0 25.6 0.4 09/26/12 37 S37:3 2.2 2.4 1.0 2.9 0.8 10/05/07 27 S27:1 2.2 2.3 7.0 2.2 0.7 09/25/12 37 S37:2 2.2 2.4 0.0 2.2 0.7 09/25/12 37 S37:2 2.2 2.4 0.0 2.2 0.7 09/25/12 37 S37:2 2.2 2.4 0.0 49.4 0.4 09/30/04 20 S20:1 25:1 24.1 1.0 49.4 0.4 09/30/04 20 S20:2 52:2 52:2 4.0 0.4 0.4 0.4 09/30/04 20 S20:2 52:2 52:2 5.0 0.4 0.4 0.4 0.4 09/30/04 20 S20:2 52:2 52:2 52:4 0.0 49.4 0.0 0.0 08/30/04 20 S20:1 52:4 4.1 0.0 49.4 0.4 09/30/04 20 S20:2 50:5 50:6 50.0 1.0 49.3 0.7 09/25/12 37 S37:2 50:0 50:0 50:0 50:0 50:0 50:0 50:0 50 | 04/02/99 | 12 | | S12:1 | | 14.5 | 15.8 | 0.5 | 7.6 | 0.5 | | | | |
| 09/17/01 14 S14:3 8.0 7.7 1.0 7.8 0.2 09/18/01 15 S15:1 8.9 8.7 1.0 8.8 0.1 11/18/02 16 S16:1 8.8 8.8 8.8 1.0 8.8 0.0 11/13/03 19 S19:4 7.8 8.6 1.0 8.2 0.5 02/23/04 20 S20:3 8.3 8.1 1.0 8.2 0.1 10/17/05 23 S23:4 8.6 8.8 1.0 8.7 0.1 8.2 0.1 10/17/05 23 S23:4 8.6 8.8 1.0 8.7 0.1 8.2 0.1 10/17/05 23 S23:4 8.6 8.8 1.0 8.7 0.1 8.2 0.1 10/17/05 23 S23:4 8.6 8.8 1.0 8.7 0.1 8.6 0.2 08/18/06 25 S25:1 8.7 8.5 1.0 8.8 0.0 1.0 8.2 0.1 10/17/05 23 S23:4 8.6 8.8 1.0 8.7 0.1 8.3 0.1 09/10/09 31 S31:3 7.3 8.1 1.0 8.3 0.1 0.7 7 0.5 02/28/11 34 S34:1 8.5 8.3 1.0 8.4 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 | | | | | | | | 1.0 | | | | | | |
| 09/18/01 15 S15:1 8.9 8.7 1.0 8.8 0.1 11/18/02 16 S16:1 8.8 8.8 1.0 8.2 0.5 11/18/03 19 S19:4 7.8 8.6 1.0 8.2 0.5 02/23/04 20 S20:3 8.3 8.1 1.0 8.2 0.1 10/17/05 23 S23:4 8.6 8.8 1.0 8.7 0.1 08/28/06 25 S25:1 8.7 8.5 1.0 8.6 0.2 08/11/08 29 S29:2 8.3 8.4 1.0 8.3 0.1 09/26/11 34 S34:1 8.5 8.3 1.0 7.7 0.5 02/28/11 34 S34:1 8.5 8.3 1.0 8.4 0.1 09/25/12 37 S37:1 8.0 8.1 1.0 8.0 0.0 09/29/29 12 S12:2 49.5 45.9 0.5 23.9 1.3 09/17/01 13 S13:2 27.6 27.7 1.0 27.7 0.1 09/27/01 14 S14:4 25.7 26.4 1.0 26.0 0.5 09/18/01 15 S15:2 25.4 25.6 1.0 25.5 0.2 03/20/03 18 S18:3 28.8 29.2 1.0 25.5 0.2 03/20/03 20 S20:4 25.9 25.2 1.0 25.5 0.5 03/26/05 22 S22:4 29.4 29.4 1.0 29.4 0.0 08/28/06 25 S25:2 27.6 27.4 1.0 27.5 0.1 08/11/08 29 S29:3 25.6 25.7 1.0 25.5 0.1 08/11/08 29 S29:3 25.6 25.7 1.0 25.6 0.1 08/20/01 17 S17:2 23.3 23.4 1.0 23.4 0.1 09/27/01 23 S23:2 25.5 24.4 1.0 24.9 0.8 10/20/212 36 S36:3 28.5 1.0 25.6 0.1 08/20/03 18 S18:1 22.7 22.7 27.7 1.0 27.8 0.1 09/27/01 36 S36:3 28.5 1.0 25.6 0.1 08/20/03 18 S18:1 22.7 22.7 22.7 1.0 22.7 0.0 09/25/12 37 S37:3 27.9 27.8 1.0 22.6 0.4 09/223/04 20 S20:1 22.4 1.0 2.4 0.0 09/26/12 37 S37:3 22.2 22.7 22.7 1.0 22.7 0.0 09/26/12 37 S37:3 22.2 22.4 1.0 22.9 0.0 03/08/05 22 S22:2 22.2 22.7 22.7 1.0 22.7 0.0 09/26/12 37 S37:3 22.9 22.4 1.0 22.0 0.7 09/25/12 37 S37:2 22.4 1.0 22.6 0.4 09/10/09 31 S31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 S37:2 22.4 1.0 22.6 0.4 09/10/09 31 S31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 S37:2 22.4 1.0 22.6 0.4 09/10/09 31 S31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 S37:2 22.4 1.0 49.4 0.4 09/13/04 20 S20:1 S27:1 4.7 0.1 0.49.4 0.4 09/13/04 21 S27:4 4.7 1.0 49.4 0.4 09/13/05 23 S23:2 S25:2 4.4 1.0 49.4 0.4 09/13/04 21 S27:4 4.7 1.0 49.4 0.4 09/13/04 21 S27:4 4.7 1.0 49.4 0.4 09/13/04 21 S27:4 4.7 1.0 49.4 0.4 09/13/09 30 S30:2 50:2 50.4 4.1 1.0 8.0 0.0 | 09/27/01 | 14 | | | | | | | | | | | | |
| 11/18/02 16 | 09/18/01 | 15 | | | | | 8.7 | | | | | | | |
| 11/13/03 19 | 11/18/02 | 16 | | | | | 8.8 | 1.0 | | 0.0 | | | | |
| 02/23/04 20 S20:3 8.3 8.1 1.0 8.2 0.1 | | | | | | | | | | | | | | |
| 101/7/05 23 S23.4 8.6 8.8 1.0 8.7 0.1 | | | | | | | | | | | | | | |
| 08/28/06 25 S25:1 | | | | | | | | | | | | | | |
| 08/11/08 29 S29:2 8.3 8.4 1.0 8.3 0.1 09/10/09 31 S31:3 7.3 8.1 1.0 7.7 0.5 02/28/11 34 S34:1 8.5 8.3 1.0 8.4 0.1 09/25/12 37 S37:1 8.0 8.1 1.0 8.0 0.0 09/23/98 11 S11:2 50.7 47.7 0.5 24.6 1.1 04/02/99 12 S12:2 49.5 45.9 0.5 23.9 1.3 09/17/01 13 S13:2 27.6 27.7 1.0 27.7 0.1 09/27/01 14 S14:4 25.7 26.4 1.0 26.0 0.5 09/18/01 15 S15:2 25.4 25.6 1.0 25.5 0.2 03/20/03 18 S18:3 28.8 29.2 1.0 29.0 0.3 02/23/04 20 S20:4 25.9 25.2 1.0 25.5 0.5 03/08/05 22 S22:4 29.4 29.4 1.0 29.4 0.0 08/28/06 25 S25:2 27.6 27.4 1.0 27.5 0.1 08/11/08 29 S29:3 25.6 25.7 1.0 25.6 0.1 08/11/08 29 S29:3 25.6 25.7 1.0 25.6 0.1 08/11/08 29 S29:3 28.3 28.5 1.0 28.4 0.1 09/25/12 37 S37:3 27.9 27.8 1.0 27.8 0.1 12/12/02 17 S17:2 23.3 23.4 1.0 23.4 0.1 03/20/03 18 S18:1 22.7 23.7 1.0 23.2 0.7 02/23/04 20 S20:1 25.1 24.1 1.0 24.6 0.7 03/08/05 22 S22:2 22.7 22.7 1.0 25.6 0.1 03/20/03 18 S18:1 22.7 23.7 1.0 23.2 0.7 02/23/04 20 S20:1 25.1 24.1 1.0 24.6 0.7 03/08/05 22 S22:2 22.7 22.7 1.0 22.6 0.4 09/15/05 23 S23:2 25.5 24.4 1.0 24.9 0.8 10/05/07 27 S27:1 22.9 22.4 1.0 22.6 0.4 09/10/09 31 S31:1 21.5 22.6 1.0 22.6 1.0 22.1 0.7 09/25/12 37 S37:2 20.4 20.7 1.0 20.5 0.2 11/18/02 16 S16:3 49.9 44.9 1.0 47.4 3.5 8 48.3 1.3 2.2 11/18/02 16 S16:3 49.9 44.9 1.0 47.4 3.5 8 48.3 1.3 2.2 11/18/02 16 S16:3 49.9 44.9 1.0 47.0 0.0 09/13/04 21 S21:4 47.1 47.0 1.0 49.4 0.4 09/13/04 21 S21:4 47.1 47.0 1.0 49.4 0.4 09/13/04 21 S21:4 47.1 47.0 1.0 49.3 0.7 09/25/12 33 S23:3 49.8 48.8 1.0 49.3 0.7 00/23/04 20 S20:2 50.2 50.4 1.0 49.3 0.7 00/13/04 21 S21:4 47.1 47.0 1.0 49.3 0.7 00/13/04 21 S21:4 47.1 47.0 1.0 48.1 0.8 03/03/09 30 S30:2 51.2 50.4 1.0 50.8 0.6 | | | | | | | | | | | | | | |
| 09/10/09 31 S31:3 | | | | | | | | | | | | | | |
| 02/28/11 34 S34:1 8.5 8.3 1.0 8.4 0.1 8.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 | | | | | | | | | | | | | | |
| 09/25/12 37 S37:1 S.0 | | | | | | | | | | | | | | |
| 09/23/98 11 S11:2 50.7 47.7 0.5 24.6 1.1 12 26.7 0.5 1.8 04/02/99 12 S12:2 49.5 45.9 0.5 23.9 1.3 09/17/01 13 S13:2 27.6 27.7 1.0 27.7 0.1 09/27/01 14 S14:4 25.7 26.4 1.0 25.5 0.2 03/28/03 18 S18:3 28.8 29.2 1.0 29.0 0.3 02/23/04 20 S20:4 25.6 1.0 25.5 0.5 03/08/05 22 S22:4 29.4 1.0 29.4 0.0 08/28/06 25 S25:2 27.6 27.4 1.0 27.5 0.1 08/11/08 29 S29:3 25.6 25.7 1.0 25.6 0.1 08/12/12 37 S37:3 27.9 27.8 1.0 27.8 0.1 12/12/02 17 S17:2 23.3 23.4 1.0 23.4 0.1 03/28/06 22 S2:2 22 22.7 22.7 1.0 22.7 0.0 12/12/02 17 S17:2 23.3 23.4 1.0 23.4 0.1 03/28/05 22 S2:2 22 22.7 22.7 1.0 22.6 0.4 03/28/06 25 S25:2 25.5 24.1 1.0 24.6 0.7 03/08/05 22 S2:2 22.2 22.7 22.7 1.0 22.7 0.0 10/17/05 23 S23:2 25.5 24.1 1.0 24.9 0.8 10/05/07 27 S27:1 22.9 22.4 1.0 22.6 0.4 09/10/9 31 S31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 S37:3 49.9 44.9 1.0 47.4 3.5 11/18/02 16 S16:3 49.9 44.9 1.0 47.4 3.5 12/12/02 17 S17:3 49.7 49.1 1.0 49.4 0.4 09/10/9 31 S31:1 S31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 S37:2 34.9 1.0 47.4 3.5 12/12/02 17 S17:3 49.7 49.1 1.0 49.4 0.4 09/10/9 31 S31:1 S31:4 47.1 47.0 1.0 47.0 0.0 10/17/05 23 S23:3 49.8 48.8 1.0 49.3 0.7 11/18/02 16 S16:3 49.9 44.9 1.0 47.0 0.0 10/17/05 23 S23:3 49.8 48.8 1.0 49.3 0.7 10/17/05 23 S23:3 523:2 55.4 48.6 47.6 1.0 50.8 0.6 10/17/05 23 S23:3 523:3 52.5 50.4 50.4 50.4 50.8 10/17/05 23 S23:3 50.2 | | | | | | | | | | | | | | |
| 04/02/99 12 S12:2 49.5 45.9 0.5 23.9 1.3 09/17/01 13 S13:2 27.6 27.7 1.0 27.7 0.1 09/27/01 14 S14:4 25.7 26.4 1.0 25.5 0.2 09/18/01 15 S15:2 25.4 25.6 1.0 25.5 0.2 03/20/03 18 S18:3 28.8 29.2 1.0 29.0 0.3 02/23/04 20 S20:4 25.9 25.2 1.0 29.4 0.0 08/28/06 25 S25:2 27.6 27.4 1.0 27.5 0.1 08/11/08 29 S29:3 25.6 25.7 1.0 25.6 0.1 02/02/12 36 S36:3 28.3 28.5 1.0 28.4 0.1 09/25/12 37 S37:3 27.9 27.8 1.0 23.4 0.1 12/12/02 17 S17:2 23.3 23.4 1.0 23.4 0.1 03/20/03 18 S18:1 22.7 23.7 1.0 23.2 0.7 02/23/04 20 S20:1 25.1 24.1 1.0 24.6 0.7 03/08/05 22 S22:2 22.7 22.7 1.0 22.7 0.0 10/17/05 23 S23:2 25.5 24.4 1.0 24.6 0.7 03/08/07 27 S27:1 22.9 22.4 1.0 22.6 0.4 09/10/09 31 S31:1 21.5 22.6 1.0 22.6 0.4 09/10/09 31 S31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 S37:2 20.4 20.7 20.7 1.0 20.5 0.2 11/18/02 16 S16:3 49.9 44.9 1.0 47.4 3.5 8 48.3 1.3 2.2 11/18/02 16 S16:3 49.9 44.9 1.0 47.4 3.5 8 48.3 1.3 2.2 11/18/02 17 S17:3 49.7 49.1 1.0 20.5 0.2 11/18/02 16 S16:3 49.9 44.9 1.0 47.4 3.5 8 48.3 1.3 2.2 11/18/02 17 S17:3 49.7 49.1 1.0 49.4 0.4 02/23/04 20 S20:2 50:2 50:6 50.0 1.0 50.3 0.4 09/13/04 21 S21:4 47.1 47.0 1.0 47.0 0.0 10/17/05 23 S23:3 49.8 48.8 1.0 49.3 0.7 10/05/07 27 S27:2 48.6 47.6 1.0 48.1 0.8 03/03/09 30 S30:2 51.2 50.4 1.0 50.8 0.6 | | | | | | | | | | | - | | | |
| 09/17/01 13 S13:2 | | | | | | | | | | | 12 | 26.7 | 0.5 | 1.8 |
| 09/27/01 14 \$14:4 25.7 26.4 1.0 26.0 0.5 09/18/01 15 \$15:2 25.4 25.6 1.0 25.5 0.2 03/20/03 18 \$18:3 28.8 29.2 1.0 29.0 0.3 02/23/04 20 \$20.4 25.9 25.2 1.0 25.5 0.5 03/08/05 22 \$22.4 29.4 29.4 1.0 29.4 0.0 08/28/06 25 \$25:2 27.6 27.4 1.0 27.5 0.1 08/11/08 29 \$29:3 25.6 25.7 1.0 25.6 0.1 09/25/12 37 \$37:3 27.9 27.8 1.0 28.4 0.1 12/12/02 17 \$17:2 23.3 23.4 1.0 23.4 0.1 03/28/03 18 \$18:1 22.7 23.7 1.0 23.2 0.7 02/23/04 20 \$20:1 | | | | | | | | | | | | | | |
| 09/18/01 15 S15:2 | | | | | | | | | | | | | | |
| 03/20/03 18 S18:3 | | | | | | | | | | | | | | |
| 02/23/04 20 \$20:4 25.9 25.2 1.0 25.5 0.5 03/08/05 22 \$22:4 29.4 29.4 1.0 29.4 0.0 08/28/06 25 \$25:2 27.6 27.4 1.0 27.5 0.1 08/11/08 29 \$29:3 25.6 25.7 1.0 25.6 0.1 02/02/12 36 \$36:3 28.3 28.5 1.0 28.4 0.1 09/25/12 37 \$37:3 27.9 27.8 1.0 27.8 0.1 12/12/02 17 \$17:2 23.3 23.4 1.0 23.4 0.1 03/20/03 18 \$18:1 22.7 23.7 1.0 23.2 0.7 02/23/04 20 \$20:1 25:1 24.1 1.0 24.6 0.7 03/08/05 22 \$22:2 22.7 1.0 22.7 0.0 10/17/05 23 \$23:2 25:5 | | | | | | | | | | | | | | |
| 03/08/05 22 S22:4 | | | | | | | | | | | | | | |
| 08/28/06 25 S25:2 27.6 27.4 1.0 27.5 0.1 08/11/08 29 S29:3 25.6 25.7 1.0 25.6 0.1 02/02/12 36 S36:3 28.3 28.5 1.0 28.4 0.1 09/25/12 37 S37:3 27.9 27.8 1.0 23.4 0.1 12/12/02 17 S17:2 23.3 23.4 1.0 23.4 0.1 03/20/03 18 S18:1 22.7 23.7 1.0 23.2 0.7 02/23/04 20 S20:1 25.1 24.1 1.0 24.6 0.7 03/08/05 22 S22:2 22.7 22.7 1.0 22.7 0.0 10/17/05 23 S23:2 25.5 24.4 1.0 24.9 0.8 10/05/07 27 S27:1 22.9 22.4 1.0 22.6 0.4 09/10/09 31 S31:1 21.5 22.6 1.0 22.1 0.7 11/18/02 16 | | | | | | | | | | | | | | |
| 08/11/08 29 \$29:3 25.6 25.7 1.0 25.6 0.1 02/02/12 36 \$36:3 28.3 28.5 1.0 28.4 0.1 09/25/12 37 \$37:3 27.8 1.0 27.8 0.1 12/12/02 17 \$17:2 23.3 23.4 1.0 23.4 0.1 03/20/03 18 \$18:1 22.7 23.7 1.0 23.2 0.7 02/23/04 20 \$20:1 25.1 24.1 1.0 24.6 0.7 03/08/05 22 \$22:2 22.7 22.7 1.0 22.7 0.0 10/17/05 23 \$23:2 25.5 24.4 1.0 24.9 0.8 10/05/07 27 \$27:1 22.9 22.4 1.0 22.6 0.4 09/10/09 31 \$31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 \$37:2 20.4 20.7 1.0 20.5 0.2 11/18/02 16 \$16:3 | | | | | | | | 1.0 | | | | | | |
| 02/02/12 36 \$36:3 \$37:3 28.3 28.5 1.0 28.4 0.1 12/12/02 17 \$17:2 23.3 23.4 1.0 23.4 0.1 03/20/03 18 \$18:1 22.7 23.7 1.0 23.2 0.7 02/23/04 20 \$20:1 25.1 24.1 1.0 24.6 0.7 03/08/05 22 \$22:2 22.7 22.7 1.0 22.7 0.0 10/17/05 23 \$23:2 25.5 24.4 1.0 24.9 0.8 10/05/07 27 \$27:1 22.9 22.4 1.0 22.6 0.4 09/10/09 31 \$31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 \$37:2 20.4 20.7 1.0 20.5 0.2 11/18/02 16 \$16:3 49.9 44.9 1.0 47.4 3.5 49.7 49.1 1.0 49.4 0.4 02/23/04 20 \$20:2 50.6 | | 25 | | | | | | 1.0 | | 0.1 | | | | |
| 09/25/12 37 \$37:3 \$27.9 27.8 1.0 27.8 0.1 12/12/02 17 \$17:2 \$23.3 23.4 1.0 23.4 0.1 8 23.0 0.5 1.4 03/20/03 18 \$18:1 22.7 23.7 1.0 23.2 0.7 02/23/04 20 \$20:1 25.1 24.1 1.0 24.6 0.7 03/08/05 22 \$22:2 22.7 22.7 1.0 22.7 0.0 10/17/05 23 \$23:2 25.5 24.4 1.0 24.9 0.8 10/05/07 27 \$27:1 22.9 22.4 1.0 22.6 0.4 09/10/09 31 \$31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 \$37:2 20.4 20.7 1.0 20.5 0.2 11/18/02 16 \$16:3 49.9 44.9 1.0 47.4 3.5 8 48.3 1.3 2.2 12/12/02 17 \$17:3 | 08/11/08 | 29 | | | | 25.6 | 25.7 | 1.0 | 25.6 | 0.1 | | | | |
| 12/12/02 17 \$17:2 23.3 23.4 1.0 23.4 0.1 8 23.0 0.5 1.4 03/20/03 18 \$18:1 22.7 23.7 1.0 23.2 0.7 02/23/04 20 \$20:1 25.1 24.1 1.0 24.6 0.7 03/08/05 22 \$22:2 22.7 22.7 1.0 22.7 0.0 10/17/05 23 \$23:2 25.5 24.4 1.0 24.9 0.8 10/05/07 27 \$27:1 22.9 22.4 1.0 22.6 0.4 09/10/09 31 \$31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 \$37:2 20.4 20.7 1.0 20.5 0.2 11/18/02 16 \$16:3 49.9 44.9 1.0 47.4 3.5 12/12/02 17 \$17:3 49.7 49.1 1.0 47.4 3.5 10/9/3/04 20 \$20:2 50.6 50.0 1.0 50.3 < | 02/02/12 | 36 | | S36:3 | | 28.3 | 28.5 | 1.0 | 28.4 | 0.1 | | | | |
| 03/20/03 18 S18:1 | 09/25/12 | 37 | | S37:3 | | 27.9 | 27.8 | 1.0 | 27.8 | 0.1 | | | | |
| 03/20/03 18 S18:1 | 12/12/02 | 17 | | S17:2 | | 23.3 | 23.4 | 1.0 | 23.4 | 0.1 | 8 | 23.0 | 0.5 | 1.4 |
| 02/23/04 20 \$20:1 25.1 24.1 1.0 24.6 0.7 03/08/05 22 \$22:2 22.7 22.7 1.0 22.7 0.0 10/17/05 23 \$23:2 25.5 24.4 1.0 24.9 0.8 10/05/07 27 \$27:1 22.9 22.4 1.0 22.6 0.4 09/10/09 31 \$31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 \$37:2 20.4 20.7 1.0 20.5 0.2 11/18/02 16 \$16:3 49.9 44.9 1.0 47.4 3.5 8 48.3 1.3 2.2 12/12/02 17 \$17:3 49.7 49.1 1.0 49.4 0.4 02/23/04 20 \$20:2 50.6 50.0 1.0 50.3 0.4 09/13/04 21 \$21:4 47.1 47.0 1.0 49.3 0.7 10/05/07 27 \$27:2 48.6 47.6 1.0 48.1 | | | | | | | | | | | | | | |
| 03/08/05 22 \$22:2 \$22.7 \$2.7 \$1.0 \$22.7 \$0.0 10/17/05 23 \$23:2 \$25.5 \$24.4 \$1.0 \$24.9 \$0.8 10/05/07 27 \$27:1 \$22.9 \$22.4 \$1.0 \$22.6 \$0.4 09/10/09 31 \$31:1 \$21.5 \$26.6 \$1.0 \$22.1 \$0.7 09/25/12 37 \$37:2 \$20.4 \$20.7 \$1.0 \$20.5 \$0.2 11/18/02 16 \$16:3 \$49.9 \$4.9 \$1.0 \$47.4 \$3.5 12/12/02 17 \$17:3 \$49.7 \$49.1 \$1.0 \$49.4 \$0.4 02/23/04 20 \$20:2 \$50.6 \$50.0 \$1.0 \$50.3 \$0.4 09/13/04 21 \$21:4 \$47.1 \$47.0 \$1.0 \$47.0 \$0.0 10/05/07 27 \$27:2 \$48.6 \$47.6 \$1.0 \$48.1 \$0.8 03/03/09 30 \$30:2 \$51.2 \$50.4 \$1.0 \$50.8 \$0.6 | | | | | | | | | | | | | | |
| 10/17/05 23 S23:2 25.5 24.4 1.0 24.9 0.8 10/05/07 27 S27:1 22.9 22.4 1.0 22.6 0.4 09/10/09 31 S31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 S37:2 20.4 20.7 1.0 20.5 0.2 11/18/02 16 S16:3 49.9 44.9 1.0 47.4 3.5 8 48.3 1.3 2.2 12/12/02 17 S17:3 49.7 49.1 1.0 49.4 0.4 02/23/04 20 S20:2 50.6 50.0 1.0 50.3 0.4 09/13/04 21 S21:4 47.1 47.0 1.0 47.0 0.0 10/17/05 23 S23:3 49.8 48.8 1.0 49.3 0.7 10/05/07 27 S27:2 48.6 47.6 1.0 48.1 0.8 03/03/09 30 S30:2 51.2 50.4 1.0 50.8 0.6 | | | | | | | | | | | | | | |
| 10/05/07 27 S27:1 22.9 22.4 1.0 22.6 0.4 09/10/09 31 S31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 S37:2 20.4 20.7 1.0 20.5 0.2 11/18/02 16 S16:3 49.9 44.9 1.0 47.4 3.5 8 48.3 1.3 2.2 12/12/02 17 S17:3 49.7 49.1 1.0 49.4 0.4 02/23/04 20 S20:2 50.6 50.0 1.0 50.3 0.4 09/13/04 21 S21:4 47.1 47.0 1.0 47.0 0.0 10/17/05 23 S23:3 49.8 48.8 1.0 49.3 0.7 10/05/07 27 S27:2 48.6 47.6 1.0 48.1 0.8 03/03/09 30 S30:2 51.2 50.4 1.0 50.8 0.6 | | | | | | | | | | | | | | |
| 09/10/09 31 S31:1 21.5 22.6 1.0 22.1 0.7 09/25/12 37 S37:2 20.4 20.7 1.0 20.5 0.2 11/18/02 16 S16:3 49.9 44.9 1.0 47.4 3.5 12/12/02 17 S17:3 49.7 49.1 1.0 49.4 0.4 02/23/04 20 S20:2 50.6 50.0 1.0 50.3 0.4 09/13/04 21 S21:4 47.1 47.0 1.0 47.0 0.0 10/17/05 23 S23:3 49.8 48.8 1.0 49.3 0.7 10/05/07 27 S27:2 48.6 47.6 1.0 48.1 0.8 03/03/09 30 S30:2 51.2 50.4 1.0 50.8 0.6 | | | | | | | | | | | | | | |
| 09/25/12 37 S37:2 20.4 20.7 1.0 20.5 0.2 11/18/02 16 S16:3 49.9 44.9 1.0 47.4 3.5 12/12/02 17 S17:3 49.7 49.1 1.0 49.4 0.4 02/23/04 20 S20:2 50.6 50.0 1.0 50.3 0.4 09/13/04 21 S21:4 47.1 47.0 1.0 47.0 0.0 10/17/05 23 S23:3 49.8 48.8 1.0 49.3 0.7 10/05/07 27 S27:2 48.6 47.6 1.0 48.1 0.8 03/03/09 30 S30:2 51.2 50.4 1.0 50.8 0.6 | | | | | | | | | | | | | | |
| 11/18/02 16 \$16:3 49.9 44.9 1.0 47.4 3.5 8 48.3 1.3 2.2 12/12/02 17 \$17:3 49.7 49.1 1.0 49.4 0.4 02/23/04 20 \$20:2 50.6 50.0 1.0 50.3 0.4 09/13/04 21 \$21:4 47.1 47.0 1.0 47.0 0.0 10/17/05 23 \$23:3 49.8 48.8 1.0 49.3 0.7 10/05/07 27 \$27:2 48.6 47.6 1.0 48.1 0.8 03/03/09 30 \$30:2 51.2 50.4 1.0 50.8 0.6 | | | | | | | | | | | | | | |
| 12/12/02 17 \$17:3 49.7 49.1 1.0 49.4 0.4 02/23/04 20 \$20:2 50.6 50.0 1.0 50.3 0.4 09/13/04 21 \$21:4 47.1 47.0 1.0 47.0 0.0 10/17/05 23 \$23:3 49.8 48.8 1.0 49.3 0.7 10/05/07 27 \$27:2 48.6 47.6 1.0 48.1 0.8 03/03/09 30 \$30:2 51.2 50.4 1.0 50.8 0.6 | | | | | | | | | | - | | 40.0 | 4.0 | 0.0 |
| 02/23/04 20 S20:2 50.6 50.0 1.0 50.3 0.4 09/13/04 21 S21:4 47.1 47.0 1.0 47.0 0.0 10/17/05 23 S23:3 49.8 48.8 1.0 49.3 0.7 10/05/07 27 S27:2 48.6 47.6 1.0 48.1 0.8 03/03/09 30 S30:2 51.2 50.4 1.0 50.8 0.6 | | | | | | | | | | | 8 | 48.3 | 1.3 | 2.2 |
| 09/13/04 21 S21:4 47.1 47.0 1.0 47.0 0.0 10/17/05 23 S23:3 49.8 48.8 1.0 49.3 0.7 10/05/07 27 S27:2 48.6 47.6 1.0 48.1 0.8 03/03/09 30 S30:2 51.2 50.4 1.0 50.8 0.6 | | | | | | | | | | | | | | |
| 10/17/05 23 S23:3 49.8 48.8 1.0 49.3 0.7 10/05/07 27 S27:2 48.6 47.6 1.0 48.1 0.8 03/03/09 30 S30:2 51.2 50.4 1.0 50.8 0.6 | | | | | | | | | | | | | | |
| 10/05/07 27 S27:2 48.6 47.6 1.0 48.1 0.8 03/03/09 30 S30:2 51.2 50.4 1.0 50.8 0.6 | | | | | | | | | | | | | | |
| 03/03/09 30 S30:2 51.2 50.4 1.0 50.8 0.6 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| 09/25/12 37 S37:4 43.9 44.1 1.0 44.0 0.1 | | | | | | | | | | | | | | |
| | 09/25/12 | 37 | | S37:4 | | 43.9 | 44.1 | 1.0 | 44.0 | 0.1 | | | | |

Please check our records against your records. Send corrections and/or updates to...

Set 1 of 9

Total Ascorbic Acid, µmol/mL



For details of the construction and interpretation of these plots, see: Duewer, Kline, Sharpless, Brown Thomas, Gary, Sowell. Anal Chem 1999;71(9):1870-8.

You, this RR

You, past RRs

<u>Sample</u> <u>Comments</u>

3rd Quartile (75%)

1st Quartile (25%)

Median (50%)

S37:1 SRM970 Lv I - distributed in RRs 11, 12, 13, 14, 15, 16, 19, 20, 23, 25, 29, 31, and 34

S37:2 Distributed in RRs 17, 18, 20, 22, 23, 27, and 31

S37:3 SRM970 Lv II - distributed in RRs 11, 12, 13, 14, 15, 18, 20, 22, 25, 29, and 36

S37:4 Distributed in RRs 16, 17, 20, 21, 23, 27, and 30

Others, this RR